

## ARTICLE OPEN



# Fear learning in unmedicated patients with anxiety disorders: a comparison of delay conditioning, fear reversal, and trace conditioning

Enric Vilajosana <sup>1,2,3</sup>, Simone Battaglia <sup>4</sup>, Pamela Chavarría-Elizondo <sup>5,6,7</sup>, Ignacio Martínez-Zalacain <sup>5,8</sup>, Asier Juaneda-Seguí<sup>5</sup>, Cristina Saiz-Masvidal<sup>5</sup>, Víctor De la Peña-Arteaga <sup>5,9</sup>, Alexander J. Shackman <sup>10,11,12</sup>, Joaquim Radua<sup>1,2,7</sup>, Carles Soriano-Mas <sup>13,15</sup> and Miquel A. Fullana <sup>1,14,15</sup>✉

© The Author(s) 2026

Anxiety disorders are common and impairing, yet their underlying mechanisms remain incompletely understood. Fear learning provides a critical translational framework for investigating pathological anxiety, bridging laboratory models and clinical phenomena. Prior studies have been limited by important methodological issues, including the inclusion of non-anxiety diagnoses, high comorbidity, and medication use. Here we examined three forms of fear learning—delay conditioning, fear reversal, and trace conditioning—in unmedicated adults with minimally comorbid primary anxiety disorders (Generalized Anxiety Disorder and Social Anxiety Disorder;  $n = 34$ ) and demographically matched controls ( $n = 102$ ). Individuals with anxiety disorders showed greater psychophysiological arousal (skin conductance responses) and reduced brain activation (assessed using functional magnetic resonance imaging) in the left dorsolateral prefrontal cortex to the learned safety cue (CS $-$ ) during the early phase of delay conditioning. Differences between individuals with anxiety disorders and controls were not evident for the learned threat versus learned safety (CS $+$  versus CS $-$ ) contrasts during delay conditioning, fear-reversal, or trace conditioning in psychophysiological arousal, brain activation, or subjective ratings. Taken together, these observations underscore the selectivity of Pavlovian learning deficits among unmedicated individuals with anxiety disorders and highlight differences in learning or using safety-related information to adaptively regulate fear.

*Translational Psychiatry* (2026)16:274; <https://doi.org/10.1038/s41398-026-03996-6>

## INTRODUCTION

Anxiety disorders, including generalized anxiety disorder (GAD), social anxiety disorder (SAD) and panic disorder (PD), affect about 12% of adults globally each year, with evidence suggesting that prevalence may be on the rise. [1, 2] These disorders can severely disrupt daily functioning, including occupational and social functioning, relationships, and overall quality of life. [3, 4] Given their impact, understanding the underlying mechanisms of anxiety disorders is essential for developing more effective or tolerable treatments. [2–4]

Pavlovian fear (or threat) learning paradigms have become a crucial translational tool in anxiety disorder research, bridging the gap between laboratory research and clinical practice. [5] These paradigms can be leveraged to study a variety of processes, including the acquisition (hereafter referred to as conditioning),

and reversal of learned fears. In fear conditioning, a formerly neutral stimulus elicits fear (conditioned stimulus, CS $+$ ) after being associated with an innately aversive stimulus (unconditioned stimulus, US). Two key forms of Pavlovian conditioning have been characterized. In delay conditioning, the presentation of the CS $+$  and US overlap in time, with the US typically co-terminating with the cue (i.e., delayed). In trace conditioning, the CS $+$  and US are separated by a brief interval, requiring the learner to hold a ‘trace’ of the CS in memory. In human research, responses to the CS $+$  are typically compared to a second cue which, because it is unpaired, is indicative of safety and remains comparatively neutral (CS $-$ ). In fear reversal, the contingencies are reversed, requiring individuals to inhibit their learned responses to previously learned threat and safety signals. [6] Across these diverse paradigms, fear responses are typically assessed using a

<sup>1</sup>Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. <sup>2</sup>Department of Medicine, Institute of Neurosciences, University of Barcelona, Barcelona, Spain. <sup>3</sup>University of Vic – Central University of Catalonia, C. Sagrada Família, 7, 08500 Vic, Barcelona, Spain. <sup>4</sup>Department of Theoretical and Applied Sciences, eCampus University, Novedrate (Como), Italy. <sup>5</sup>Psychiatry and Mental Health Group, Neuroscience Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. <sup>6</sup>Department of Clinical Sciences, Universitat de Barcelona, Barcelona, Spain. <sup>7</sup>Network Center for Biomedical Research on Mental Health (CIBERSAM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. <sup>8</sup>Radiology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Carrer de Feixa Llarga SN, 08907 Barcelona, Spain. <sup>9</sup>Sant Pau Mental Health Research Group, Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain. <sup>10</sup>Department of Psychology, University of Maryland, College Park, MD 20742, US. <sup>11</sup>Neuroscience and Cognitive Science Program, University of Maryland, College Park, MD 20742, US. <sup>12</sup>Maryland Neuroimaging Center, University of Maryland, College Park, MD 20742, US. <sup>13</sup>Department of Social Psychology and Quantitative Psychology, Institute of Neurosciences, Universitat de Barcelona (UB), and Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) and CIBERSAM, Barcelona, Spain. <sup>14</sup>Adult Psychiatry and Psychology Department, Institute of Neurosciences, Hospital Clinic, Barcelona, Spain. <sup>15</sup>These authors contributed equally: Carles Soriano-Mas, Miquel A. Fullana. ✉email: mafullana@clinic.cat

Received: 1 July 2025 Revised: 19 February 2026 Accepted: 16 March 2026

Published online: 02 April 2026

mixture of subjective ratings; psychophysiological responses, such as the skin conductance response (SCR); and neuroimaging measures, such as functional magnetic resonance imaging (fMRI). [7, 8] Delay conditioning is associated with higher arousal and more negative valence ratings, increased SCRs, and greater activation in regions of the salience / central autonomic–interoceptive network (e.g., anterior insula, dorsal anterior cingulate cortex, thalamus, and sensory cortices) when comparing CS+ to CS−. [7, 9] Trace conditioning shows a similar pattern in subjective ratings and SCRs, but could be additionally characterized by increased hippocampal activation. [10] During fear reversal, subjective ratings and SCRs “flip” to follow the new CS+, and neural activity shifts accordingly: salience-network regions track the new CS+, while regions such as the ventromedial prefrontal cortex and orbitofrontal cortex contribute to flexible re-learning. [6, 11]

Both fear conditioning and fear reversal processes may play a crucial role in anxiety disorders. Increased susceptibility to conditioning (e.g., heightened fear responses to neutral stimuli) may explain persistent fear associations in patients with anxiety disorders. Conversely, impaired fear reversal may reflect difficulty adapting to changing cues, such as failing to respond to new threats or overreacting to now-safe stimuli. [12] Flexible updating of threat associations is also key to effective treatment of anxiety disorders. [13]

Studies assessing fear conditioning and fear reversal in individuals with anxiety disorders have yielded inconsistent findings. A comprehensive recent meta-analysis of delay-conditioning paradigms found no consistent differences in threat (CS+) reactivity among individuals with mixed anxiety and trauma diagnoses, as indexed by psychophysiological responses (SCR). [14] Nevertheless, patients did show heightened responses to safety cues (CS-) across multiple measures, including fear-potentiated startle, US expectancy, and affective ratings, suggesting aberrant safety learning rather than heightened fear conditioning. [14] While an important advance, these observations are limited by the inclusion of medicated individuals. Current anti-anxiety medications can have significant effects on fear learning—including safety learning—processes. [15] Moreover, this meta-analysis—and previous similar work [16]—combined individuals with a wide variety of disorders that are not currently classified as anxiety disorders (e.g., obsessive–compulsive disorder [OCD] or post-traumatic stress disorder [PTSD]). [17] The meta-analysis also did not account for comorbidity, which is a critical inferential limitation given that approximately 60% of individuals with an anxiety disorder also meet criteria for a depressive or other anxiety disorder. [2]

Fear reversal in anxiety disorders remains understudied. In one of the few published studies, Savage and colleagues reported no significant differences in ratings, psychophysiological arousal, or brain activation measures during reversal between unmedicated young patients (aged 15–25) with SAD and healthy controls. [18] In a predominantly medicated GAD sample, Roberts et al. found that those patients had a significantly higher overall SCR and a reduced differential SCR (CS+ > CS-) compared to healthy controls during the early, but not the late, phase of fear reversal. [15]

The study by Roberts et al. underscored the importance of temporal dynamics in human fear learning. For example, previous research suggests that learning during fear acquisition is typically stronger in early trials than in later ones. [19] In neuroimaging studies, early trials of fear acquisition are thought to more effectively capture the activation of specific brain regions. [9] Moreover, theoretical and computational models suggest that the largest prediction error—and therefore the greatest amount of learning—occurs when the CS–US contingency is first introduced, i.e., during the early trials. [20] Finally, besides the study by Roberts et al, several previous fear learning studies have found patient-control differences only in early or late learning phases. [21, 22]

Trace fear conditioning has received even less empirical attention, and no prior research has specifically investigated trace conditioning in individuals with anxiety disorders. This is unfortunate because trace paradigms may better reflect real-life situations where cues and aversive outcomes are temporally separated [23] and are considered “weak” situations compared to the “strong” delay paradigms. [24, 25] Weakening the situation, by reducing the certainty, proximity, or intensity of the US, may enhance sensitivity to group differences. [24]

To address these fundamental questions, the present study investigated delay conditioning, fear reversal, and trace conditioning in an unmedicated sample of 34 adults with DSM-5 [17] anxiety diagnoses (primarily GAD or SAD), with minimal or no comorbidity, and 102 age and gender-matched controls. Consistent with recent recommendations, [7] we acquired a comprehensive set of fear measures, including subjective ratings, SCR, and fMRI. Based on previous research, [14, 15] we anticipated that individuals with anxiety disorders would show 1) heightened responses to the CS− during delay conditioning, indicating impaired safety learning; 2) reduced differential conditioning during fear reversal, reflecting difficulties in updating threat and safety associations; and heightened fear conditioning or deficient safety learning during delay conditioning. Based on previous research (see above), we generally expected group differences to be more evident during the earlier portion of each learning phase (e.g., early delay acquisition).

## METHODS

### Participants

Participants were recruited as part of a larger study focused on identifying predictors of pathological anxiety. Here, we investigated potential differences in Pavlovian fear conditioning in unmedicated individuals with anxiety disorders ( $n = 34$ ) and healthy controls ( $n = 102$ ), selected from a larger sample ( $n = 135$ ). The two groups were matched on gender distribution and age (Table 1). Diagnostic eligibility was determined by an experienced clinician using the MINI International Neuropsychiatric Interview. [26] For descriptive purposes, participants completed self-reported measures of anxiety, depressive symptoms, and dispositional negative affect (see “**Recruitment procedures**” and “**Self-report measures**” in Sup. Mat.). All participants provided informed written consent. The study was approved by the ethics committee at Hospital de Bellvitge in Barcelona (protocol # PR144/16).

### Fear learning assessment

Participants completed two fear-learning tasks in the scanner while subjective ratings, SCR, and fMRI were assessed. The first task assessed delay fear conditioning and fear reversal, whereas the second task assessed trace fear conditioning. The order of the tasks was counter-balanced across participants. In both tasks, the unconditioned stimulus (US) was an individually calibrated electric shock, designed to be “unpleasant but not painful”. In the delay/reversal task, the conditioned stimuli (CSs) were blue and yellow spheres presented against a black background, whereas in the trace task, the CSs were waves, dots, or triangles. Both tasks used the same procedures for subjective ratings, SCR, and fMRI data collection, and participants received identical instructions (see “**Fear learning assessment**” in the Sup. Mat.).

### Delay fear conditioning and fear reversal task

We leveraged a previously validated delay fear acquisition/reversal task that encompassed three phases: pre-conditioning, fear conditioning, and fear reversal [27] (Fig. 1A, B). During pre-conditioning, the to-be-conditioned CS+ and CS− (2000 ms) were each presented five times. The US (250 ms) was never presented. During conditioning, the CS+ and US co-terminated on one-third of trials, enabling us to examine skin-conductance and fMRI responses unconfounded by US presentation. The CS− was never paired with the US. During fear reversal, the CS-shock contingency was reversed (newCS+ :  $p = 33.3\%$ ; newCS− :  $p = 0.0\%$ ). Across the conditioning and reversal phases, there were a total of 15 CS+/newCS+ trials (5 reinforced) and 10 CS−/newCS− trials (pseudorandomized). During the conditioning phase, the second CS+ trial was reinforced. During the reversal phase, the first presentation of the new CS+ was reinforced. CS

**Table 1.** Demographic and clinical characteristics of participants.

Variable	Healthy Controls (n = 102) Mean (SD)	Patients with Anxiety Disorders (n = 34) Mean (SD)	Significance
Age	25.6 (4.82)	25.6 (3.8)	<i>n.s.</i>
Females (n, %)	57 (55.9%)	19 (55.9%)	<i>n.s.</i>
<b>Self-report questionnaires</b>			
STAI-T (0–60)	18.68 (9.66)	29.15 (11.8)	$p < 0.001$
IUS (27–135)	50.74 (15.56)	72.68 (25.76)	$p < 0.001$
LSAS (0–144)	22.23 (12.39)	32.47 (17.54)	$p < 0.05$
GAD-Screening Scale (0–12)	2.3 (2.13)	6.53 (3.14)	$p < 0.001$
PSWQ-11 (11–55)	25.72 (9.4)	36.41 (10.08)	$p < 0.001$
DASS-S (0–21)	3.41 (2.98)	7.09 (4.23)	$p < 0.001$
DASS-A (0–21)	1.38 (1.88)	3.47 (3.29)	$p < 0.05$
DASS-D (0–21)	1.77 (2.03)	4.88 (4.76)	$p < 0.001$
Shock aversiveness <sup>a</sup> (1–10)	9.32 (0.84)	9.35 (0.72)	<i>n.s.</i>
<b>Diagnoses</b>		<b>Number of participants (%)</b>	
GAD		24 (70.6)	
GAD plus another anxiety disorder		4 (11.8) <sup>b</sup>	
SAD		5 (14.7)	
SAD plus agoraphobia		1 (2.9)	

STAI-T state-trait anxiety inventory, trait version, IUS intolerance of uncertainty scale, LSAS liebowitz social anxiety scale, GAD-Screening generalized anxiety disorder – screening scale, PSWQ-11 penn state worry questionnaire, DASS-21-S depression, anxiety and stress scales – stress subscale, DASS-21-A depression, anxiety and stress scales – anxiety subscale, DASS-21-D depression, anxiety and stress scale – depression subscale, GAD generalized anxiety disorder, SAD social anxiety disorder, *n.s.* non-significant.

<sup>a</sup>Average shock aversiveness for the two tasks (see Supplementary Methods).

<sup>b</sup>GAD+Panic Disorder (n = 1); GAD + SAD (n = 3)

stimuli were counterbalanced across participants. Across all phases, the inter-trial interval (ITI) between CS trials was 12 s, during which a white fixation cross (CFix) was presented.

### Trace fear conditioning task

The trace conditioning task encompassed two phases: pre-conditioning (baseline), and trace fear conditioning (Fig. 1C, D). During pre-conditioning, two to-be-conditioned CS+ and one CS- were each presented twice. The US (250 ms) was never presented. During conditioning, the US was presented at the end of the “trace” (blank screen), 1600–2000 ms following CS+ offset. One of the CS+ was reinforced on 50% of trials (CS+50) and the other was reinforced on 81% of trials (CS+81). Procedures for the CS- were similar, but it was never paired with the US. During the conditioning phase, each of the three CS was presented 16 times (order pseudorandomized; 11.6–12.0-s ITI). CS stimuli were counterbalanced across participants.

### Measures of conditioned fear

**Subjective ratings.** Immediately after each learning phase (pre-conditioning, conditioning, and reversal for the delay/reversal task, and pre-conditioning and conditioning for the trace conditioning task), participants rated each CS on two five-point Likert scales of valence and arousal related to anxiety (Self-Assessment Manikins [28]), with higher scores indicating greater valence and increased arousal (see “Measures of conditioned fear” in the Sup. Mat.).

### Skin conductance responses

SCR data were acquired in the scanner during the two tasks, and the response to each CS (CS+, CS-, for the delay task; newCS+ and newCS- for the reversal task; and CS+81, CS+50, and CS-, for the trace task) calculated. The acquisition and (pre)processing of SCR data followed standard procedures. [29] (see “Measures of conditioned fear” in the Sup. Mat.).

### Brain activation

Neuroimaging data were acquired using a Phillips Ingenia 3 T scanner (32-channel head-coil). For details on imaging acquisition and (pre)processing, see “Measures of conditioned fear - Brain activation” in the Sup. Mat.


The two fear learning tasks were programmed in E-Prime 2.0 and displayed on an MRI-compatible back-projection screen. Both tasks were similar in duration (~16 min) and separated by a 15 min break.

**First-level fMRI modeling.** Each participant’s preprocessed time series was entered into a first-level general linear model (GLM) analysis. The onsets of each CS event type were modeled separately for each task by convolving them with a canonical hemodynamic response function. Six motion parameters were included as nuisance covariates. For the delay task, contrast images were computed for CS+ > CS- (excluding reinforced trials to avoid contamination from the US) and CS- > CFix. Fixation-cross ITIs contributed the implicit baseline. For the reversal task, contrast images were estimated for newCS+ > newCS-, also excluding reinforced trials. For the trace conditioning task, contrasts were computed for CS+<sub>50</sub> > CS-, CS+<sub>81</sub> > CS-, and CS+<sub>50</sub> > CS+<sub>81</sub> and all CS+ trials were included as increasing the ITI and ISI (inter-stimuli interval) minimized the risk of US-related confounds. ISIs ranged from 5.35–5.75 s.

### Statistical analyses

Two-sample Student’s *t*-tests and a chi-square test were used to confirm that patients and controls were adequately matched on demographic characteristics and differed in self-report measures of anxiety. Repeated-measures tests were used to confirm the absence of significant differences between the to-be-conditioned CSs during the pre-conditioning phase of the delay (Student’s *t*-tests) and trace (ANOVA) conditioning tasks (see “Preconditioning Analyses” in Sup. Mat.).

Subjective ratings and SCR data were analyzed using a series of mixed-model ANOVAs with CS as a within-subject factor and group as a between-subject factor. For the acquisition phase of the delay task, there were 2 levels of CS (CS+, CS-). For the reversal phase, there were 2 levels of the CS (newCS+, newCS-). For the trace conditioning task, there were 3 levels of the CS (CS+50, CS+81, CS-). For the delay task, the 5 reinforced CS+/newCS+ trials were censored from SCR analyses to avoid US confounding. For the trace task, where a longer CS-US interval prevented US confounding, all trials were included. Post hoc comparisons were conducted using the Bonferroni test ( $\alpha = 0.05$ ), and the Greenhouse-Geisser correction was applied when necessary. Effect sizes are reported using partial eta squared ( $\eta^2_p$ ).



**Fig. 1 Fear conditioning fMRI paradigms.** Delay fear conditioning and fear reversal task. During pre-conditioning, the US was omitted. During conditioning, the US (lightning bolt) was paired with one of the spheres on 33.3% trials (CS+), but not the other (CS-). During fear reversal, the CS-shock contingency was reversed to create newCS+ and newCS-. Red boxes indicate unpaired CS+ trials (A). Detailed timeline of events within delay conditioning/reversal trials (B). Trace fear conditioning task. During pre-conditioning, the US was omitted. During conditioning, the US was paired with two of the CS (CS+ 50: 50%; CS+ 81: 81%), but not the third (CS-) (C). Detailed timeline of events within trace conditioning trials (D). CFix Cross-fixation, CS conditioned stimulus, ms milliseconds, US unconditioned stimulus.

Neuroimaging analyses closely paralleled the approach used for SCR. Between-group differences in neuroimaging contrasts (CS+ > CS- and CS->CFix for delay conditioning; newCS+ > newCS- for fear reversal; CS+ 81 > CS-, CS+ 50 > CS-, and CS+ 81 > CS+ 50 for trace conditioning) were assessed using two-sample *t*-tests. Whole-brain statistical significance was determined using a cluster-level family-wise error (FWE) correction at  $p < 0.05$ , with clusters formed of contiguous voxels with  $p < 0.001$ .

Consistent with other recent work, [7, 19, 21, 22, 30] we generally expected group differences to be more evident during the early portion of each learning phase. Therefore, we computed a second set of 'disaggregated' SCR and fMRI analyses that incorporated early-versus-late phase as a within-subject factor. For the delay and reversal tasks, early and late phases were defined as the first and last five unreinforced CS+ /newCS+ and CS-/newCS- trials, respectively. For trace conditioning, they were defined as the first and last eight trials of CS+ 81, CS+ 50, and CS-. Note that disaggregated analyses for subjective ratings were not possible because these ratings were collected at the end of the phase.

We repeated all main analyses of subjective ratings, SCR, and fMRI data, including age and gender as covariates. Although task order (first delay/reversal or first trace) was counterbalanced, to assess potential order effects, we also repeated the main analyses with task order included as a factor.

## RESULTS


Our patient sample ( $n = 34$ ) included 28 individuals with a primary diagnosis of GAD and 6 individuals with a primary diagnosis of SAD. There were no significant differences in age or biological sex distribution between patients and controls. Patients exhibited significantly higher anxiety, depressive symptoms, and

dispositional negative affect. Groups did not differ in the perceived aversiveness of the shock US (Table 1).

During pre-conditioning of the delay conditioning/reversal task, no significant differences were observed within each group in responses to the to-be CS+ and to-be CS- across any conditioned fear measures, including subjective ratings, SCR, or brain activation (see Supplementary Fig. 1 and Supplementary Table 2). Similarly, during pre-conditioning of the trace conditioning task, no significant differences were found in arousal and valence ratings for either group or SCR for the patient group. However, in the control group, SCR responses were greater for the to-be CS+ 81 compared to both to-be CS+ 50 and to-be CS- (see Supplementary Fig. 2 and Supplementary Table 3). Additionally, both groups exhibited increased activation in the visual cortex in the CS+ 81 > CS- contrast.

### Delay fear conditioning

In the aggregated analyses that included all trials, both controls (Fig. 2A, B, C) and patients (Fig. 2E, F, G) showed evidence of successful delay fear conditioning in SCR and subjective ratings, with significantly larger SCR to the CS+ compared to the CS-, and significantly higher arousal and lower valence ratings for the CS+ compared to the CS- (all  $ps < 0.001$ ). Although SCR was, on average, higher among patients than controls ( $F(1,127) = 6.20$ ,  $p < 0.05$ ,  $\eta^2_p = 0.047$ ), the Group  $\times$  CS type interaction was not significant for SCR, arousal, or valence (all  $F_s \leq 0.33$ , all  $ps \geq 0.56$ ; Supplementary Table 4), indicating no significant between-group differences in differential conditioning (CS+ vs. CS-). However, our planned analyses focused on safety learning showed that SCR



**Fig. 2** Delay fear conditioning in healthy controls ( $n = 102$ ) and patients with anxiety disorders ( $n = 34$ ). LEFT: Skin conductance responses (SCR) (A) subjective ratings of arousal (B) and valence (C) and functional magnetic resonance imaging (fMRI) responses (D) during delay fear conditioning in healthy controls. RIGHT: SCR (E) subjective ratings of arousal (F) and valence (G) and fMRI responses (H) during delay conditioning in patients with anxiety disorders. For subjective ratings, data refer to the responses to the CS+ or CS- at the end of the conditioning phase. For SCR, data refer to the average responses to the unreinforced CS+ trials and the CS- trials during conditioning. For fMRI, data refer to the CS+ > CS- contrast, using the same trials as for the SCR. To facilitate visual comparison, the t-maps were converted to effect sizes by dividing them by the square root of the sample size. These maps were then thresholded at 0.5, representing the lower boundary of effect sizes within significant regions observed in the control group. Error bars indicate standard error of the mean (SEM).  $*p < 0.001$ . fMRI figures display slices in the three orthogonal directions that best represent each group's results. These images are not exhaustive, and full details can be found in the referenced supplementary tables. While slice selection may vary between control and patient groups, it is aimed at highlighting the most characteristic neural activations for each group across the studied contrasts.

to the CS- was greater in patients compared with controls [Patients:  $M(SD) = 0.13 (0.11)$ ; Controls:  $M(SD) = 0.07 (0.08)$ ;  $t(127) = -3.39$ ,  $p < 0.001$ ]. Notably, the absence of a significant Group  $\times$  CS type interaction also indicates that SCR to the CS+ was elevated in patients relative to controls. Similar effects were not observed for arousal or valence ratings.

In the disaggregated (early and late) SCR analyses, the ANOVA revealed a significant main effect of group ( $F(1,127) = 6.20$ ,  $p = 0.014$ ,  $\eta^2 p = 0.047$ ) and a three-way interaction between CS type, group, and phase ( $F(1,127) = 4.18$ ,  $p = 0.043$ ,  $\eta^2 p = 0.032$ ; Supplementary Table 5). Post-hoc analyses revealed that controls exhibited successful differential conditioning (CS+ vs CS-) during early conditioning ( $p < 0.05$ ; Fig. 3A), whereas patients did not ( $p = 0.974$ ; Fig. 3B). This reflected the fact that patients exhibited higher SCR to the CS- than controls during early conditioning [Patients:  $M(SD) = 0.18 (0.16)$ ; Controls:  $M(SD) = 0.09 (0.10)$ ,  $t(127) = -3.45$ ,  $p < 0.001$ ] (Fig. 3A, B).


The aggregated fMRI analyses provided evidence of successful conditioning in controls (Fig. 2D) and patients (Fig. 2H). Specifically, the CS+ > CS- contrast revealed increased activation in regions previously associated with fear conditioning, [8, 9] including the supramarginal gyrus, anterior insular cortices (extending into the frontal operculum), anterior and middle

cingulate cortex, and thalamus (see Supplementary Tables 6 and 7). Group differences were negligible in the aggregated and disaggregated analyses for the CS+ vs CS- contrast.

For the CS- > Cfix contrast (safety learning), the aggregated fMRI analyses revealed no group differences. However, in the disaggregated analyses, patients showed significantly reduced activation to the safety cue (CS-) in the left dorsolateral prefrontal cortex (dlPFC) during the early phase of conditioning (Fig. 3C, D). No group differences were observed in response to the CS- during the late phase.

#### Fear reversal

For the aggregated analyses, both controls (Fig. 4A, B, C) and patients (Fig. 4E, F, G) showed evidence of successful fear reversal in SCR and subjective ratings, with significantly larger SCR to the new CS+ compared to the new CS-, and significantly higher arousal and lower valence ratings scores to the new CS+ compared to the new CS- (all  $F_s \geq 87.19$ , all  $p_s < 0.001$ ). The Group  $\times$  CS type interaction was not significant for SCR, arousal, or valence (all  $F_s \leq 2.22$ , all  $p_s \geq 0.138$ ) (Supplementary Table 8), indicating no significant group differences. Similar conclusions were evident for the disaggregated SCR analyses (Supplementary Tables 9).



**Fig. 3** Delay fear conditioning responses during early and late phases in healthy controls ( $n = 102$ ) and patients with anxiety disorders ( $n = 34$ ). Skin conductance responses (SCR) data represent average responses to the first and last five CS+ and CS- trials (unreinforced CS+ trials only) (A, B). fMRI results for the CS-  $\rightarrow$  fixation cross contrast (safety learning) during the same trials show significantly less activation in patients compared to healthy controls during early conditioning within a cluster in the left dorsolateral prefrontal cortex (C). Violin plot depicting mean beta values within the significant cluster for each group (D). \* $p < 0.05$ , \*\*\* $p < 0.001$ .


fMRI results (new CS+  $>$  new CS- contrast) showed evidence of successful fear reversal in both controls (Fig. 4D) and patients (Fig. 4H), with increased brain activation across several brain regions, including the supramarginal gyrus, anterior insula (extending to the temporal pole), thalamus, and midcingulate cortex (see Supplementary Tables 10 and 11). Note that the regions activated during reversal are largely overlapping to those observed during conditioning. Group differences were negligible in the aggregated and disaggregated analyses.

Rather than calculating fear reversal by directly comparing CS+ and CS- responses during reversal, some recent fear reversal studies have separately assessed *threat reversal* and *safety reversal*. [27] In principle, this approach provides a more precise measure of the ability to update and inhibit conditioned fear responses as stimulus-outcome contingencies change. Nevertheless, groups did

not differ in SCR, subjective ratings, or neural activation during the switch from CS- to CS+ or vice versa (SCR/Ratings: all  $t_s \leq |1.47|$ , all  $p_s \geq 0.145$ ; fMRI: see Sup. Mat.: **Additional Analyses** and Supplementary Table 12).

#### Trace fear conditioning

There was evidence of successful trace conditioning within both groups and most measures. Both controls (Fig. 5A, B, C) and patients (Fig. 5F, G, H) exhibited significantly larger SCR, higher arousal, and lower valence to CS+ 81 and CS+ 50 compared to CS- (all  $p_s < 0.001$ ). When comparing CS+ 81 to CS+ 50, both controls and patients showed significantly larger SCRs (Fig. 5A, F) and lower valence ratings (Fig. 5C, H) for CS+ 81 than CS+ 50 ( $p_s < 0.02$ ). In contrast, arousal ratings to CS+ 81 and CS+ 50 did not differ significantly in either the controls (Fig. 5B) or the



**Fig. 4** Fear reversal in healthy controls ( $n = 102$ ) and patients with anxiety disorders ( $n = 34$ ). LEFT: SCR (A) subjective ratings of arousal (B) and valence (C) and fMRI responses (D) during fear reversal in healthy controls. RIGHT: SCR (E) subjective ratings of arousal (F) and valence (G) and fMRI responses (H) during fear reversal in patients with anxiety disorders. For SCR, data refer to the average responses to the unreinforced new CS+ trials and the new CS- trials during fear reversal. For fMRI, data refer to the new CS+ > new CS- contrast using the same trials as for SCR. To facilitate visual comparison, the t-maps were converted to effect sizes by dividing them by the square root of the sample size. These maps were then thresholded at 0.5, representing the lower boundary of effect sizes within significant regions observed in the control group. Error bars indicate standard error of the mean (SEM).  $*p < 0.001$ . fMRI figures display slices in the three orthogonal directions that best represent each group's results. These images are not exhaustive, and full details can be found in the referenced supplementary tables. While slice selection may vary between control and patient groups, it is aimed at highlighting the most characteristic neural activations for each group across the studied contrasts.

patients (Fig. 5G) ( $ps > 0.99$ ). The Group  $\times$  CS type interaction was not significant for SCR, arousal, or valence (all  $Fs(2,244) < 2.26$ , all  $ps > 0.11$ ) (Supplementary Table 13). The main effect of group was also non-significant, indicating that SCR, arousal, and valence levels were generally similar across groups (all  $Fs(1,122) < 3.46$ , all  $ps > 0.07$ ). Similar conclusions were evident for the disaggregated analyses (Supplementary Table 14).

fMRI findings provided evidence of successful trace conditioning in both controls (Fig. 5D, E) and patients (Fig. 5I, J) for the contrasts CS + 50 > CS- and CS + 81 > CS-. In each group, these contrasts were associated with increased activation across several regions, including the thalamus, supplementary motor area (SMA), supramarginal gyrus, precentral/postcentral gyri, and the insula extending into the inferior frontal operculum (see Supplementary Tables 15–18). For the CS + 81 > CS + 50 contrast, controls showed increased activation in several regions, including the temporal/occipital middle gyri, putamen, hippocampus, thalamus, and precentral/postcentral gyri (see Supplementary Table 19 and Supplementary Fig. 3). However, this contrast did not yield significant activation increases in patients.


Direct group comparisons revealed no significant differences in brain activation between patients and controls for any of the three contrasts (CS + 50 > CS-, CS + 81 > CS-, CS + 81 > CS + 50), indicating broadly similar neural responses. Comparable patterns were observed in the disaggregated analyses.

**Sensitivity analyses.** None of the key conclusions regarding patient-control differences changed when gender or age were included as covariates (see Supplementary Tables 20–22). When task order was included as a factor, a significant patient-control difference emerged in the disaggregated analyses for the CS+ > CS- contrast. Specifically, during early delay fear conditioning, patients showed greater deactivation to the CS- in a cluster located in the left dlPFC (Supplementary Table 23). For all other measures and contrasts, task order did not materially alter the main findings regarding patient-control differences (Supplementary Tables 24–26).

## DISCUSSION

This is the first study to jointly examine delay conditioning, fear reversal, and trace conditioning across subjective, psychophysiological, and neural measures in unmedicated individuals with anxiety disorders and matched controls. Overall, our findings suggest that individuals with anxiety disorders show impaired safety learning during the early stages of delay conditioning but do not exhibit marked alterations in either fear reversal or in trace conditioning.

Previous studies using delay fear conditioning paradigms in unmedicated individuals with anxiety disorders, as currently defined, remain limited. Pöhlchen et al. [31] found no significant



**Fig. 5 Trace fear conditioning in healthy controls (n = 102) and patients with anxiety disorders (n = 34).** LEFT: SCR (A) subjective ratings of arousal (B) and valence (C) and fMRI responses for the contrasts CS + 50 > CS- (D) and CS + 81 > CS- (E) during trace fear conditioning in healthy controls. RIGHT: SCR (F) subjective ratings of arousal (G) and valence (H) and fMRI responses for the contrasts CS + 50 > CS- (I) and CS + 81 > CS- (J) during trace fear conditioning in patients with anxiety disorders. For subjective ratings, data refer to the responses to the CS + 50, CS + 81 or CS- at the end of the trace conditioning phase. For SCR, data refer to the average responses to the unreinforced CS + 50 and CS + 81 trials and the CS- trials during trace conditioning. For fMRI, data refer to the above-mentioned contrasts using the same trials as for SCR. To facilitate visual comparison, the t-maps were converted to effect sizes by dividing them by the square root of the sample size. These maps were then thresholded at 0.5, representing the lower boundary of effect sizes within significant regions observed in the control group. Error bars indicate standard error of the mean (SEM). \* $p < 0.001$ . fMRI figures display slices in the three orthogonal directions that best represent each group's results. These images are not exhaustive, and full details can be found in the referenced supplementary tables. While slice selection may vary between control and patient groups, it is aimed at highlighting the most characteristic neural activations for each group across the studied contrasts.

differences in subjective (expectancy ratings) or psychophysiological (SCR, FPS, pupillometry) measures of conditioned fear (CS+ vs CS- difference) when comparing patients with anxiety disorders (specific phobia, SAD, agoraphobia, and PD) to healthy controls. Similarly, several prior studies focusing on GAD, SAD and PD patients reported no differences between patients and controls in

psychophysiological (FPS or SCR) or subjective (expectancy ratings) conditioned fear measures. [32–36]

In our aggregated analysis, which included all trials, we also found no group differences in cue differentiation (CS+ vs. CS-) during delay conditioning. However, patients showed heightened SCR responses to the CSs, showing overall higher physiological

responding. Specifically, patients showed increased safety cue (CS-) SCR. Although this effect was evident in our aggregated results, phase-specific analyses indicated that this alteration largely is most pronounced during the early phase of delay fear conditioning. Mirroring this effect, fMRI results revealed decreased activation to the safety cue (CS-) in the left dlPFC during the early phase of conditioning. The dlPFC plays a key role in emotion regulation, [37–39] and greater dlPFC activation in response to safety cues has been linked to fear inhibition. [40, 41] Thus, reduced dlPFC engagement in patients may reflect difficulties in downregulating responses to the CS-, particularly during the early stages of learning Pavlovian safety associations. Methodologically, our observations underscore the importance of cue- and phase-specific analyses for understanding the alterations in fear learning that mark individuals with pathological anxiety. [42]

Contrary to our expectations, we did not find differences in fear reversal between our patient and control groups. Our results are aligned with those of Savage et al. [43], who also found no differences in subjective ratings, SCR, or brain activation during fear reversal in unmedicated patients with SAD compared to healthy controls or patients with major depressive disorder. Roberts et al. [15] reported reduced differential SCR responses in GAD patients compared to controls during the early but not the late phase of fear reversal. This study included mostly (79%) medicated participants, and as noted in the introduction, medication may be a key confound in fear learning studies. [16] Variation in the type of CSs used could also influence these differences: unlike Savage et al. and the current study, which employed geometric figures, Roberts et al. [15] used angry faces as CS. Two additional factors may help explain the absence of group differences for fear reversal. First, fMRI reversal effects are typically modest and often restricted to specific regions of interest (e.g., OFC, vmPFC); therefore, our conservative whole-brain corrections may have obscured potential group differences. Second, from a theoretical perspective, reversal learning deficits may be more characteristic of other mental disorders, such as OCD, than of anxiety disorders. [15, 44]

We anticipated that using a trace conditioning paradigm, a “weak situation” (see **Introduction**), with two CS+ stimuli featuring different pairing rates would enhance the detection of fear learning differences between individuals with anxiety disorders and controls. However, our findings did not support this hypothesis. To our knowledge, ours is the first study that has directly compared trace fear conditioning between patients with anxiety disorders and healthy controls. Our trace interval was relatively short (1.6–2 s), and it is possible that differences may have emerged with longer intervals—a possibility that warrants further exploration.

Overall, and in line with several previous reports, [31–36, 43] our results suggest that anxiety disorders, as a group, are not characterized by robust alterations in most fear learning processes investigated here. However, it remains possible that diagnoses not represented here (e.g., panic disorder) do show such alterations. Additionally, disruptions in other fear learning mechanisms—such as fear extinction learning, [45] fear generalization [46] or fear extinction recall [30], may characterize anxiety disorders. The “anxiety disorders” category has changed over the years and the current versions of the most employed classification systems (DSM-5 [17] and ICD-11 [47]) do not include post-traumatic stress disorder (PTSD). A recent large-scale study on the neural correlates of delay fear conditioning [9] found increased brain activation during fear conditioning in multiple regions among patients with “anxiety-related disorders” (a category including anxiety disorders, OCD, and PTSD) compared to healthy controls. Using linear models and normative modeling analyses, [48] the study further revealed that alterations in delay fear conditioning were characteristic of PTSD and OCD but not of GAD or SAD. When considered alongside our findings and previous research on PTSD,

[49] these results suggest that fear conditioning abnormalities, at least in the context of delay fear conditioning, may be more strongly associated with PTSD than with other “anxiety-related disorders.” Given that PTSD and OCD are often linked to greater severity and functional impairment compared to other anxiety disorders, [50, 51] and that fear conditioning abnormalities have also been reported in a broader spectrum of mental disorders [52] (e.g., schizophrenia), we speculate that such abnormalities may serve as a transdiagnostic marker of severity rather than being specific to any single diagnosis. In this view, altered fear conditioning could reflect a general liability dimension that varies continuously with symptom burden, rather than mapping into specific psychiatric categorization. This hypothesis could be tested in future research by incorporating fear conditioning measures across individuals with various mental disorder diagnoses and assessing them using a standardized measure of severity and functional impairment.

Our null findings regarding differences between patients and controls for most fear learning contrasts may also reflect methodological factors. Human fear conditioning experiments are influenced by multiple variables, including the type and number of CSs and USs, the reinforcement (pairing) rate, and the measures used to assess fear responses and how they are collected, yet the effects of these factors are only beginning to be systematically understood. [9, 19] For example, some authors have emphasized the importance of using fear-relevant CSs (e.g., angry faces in SAD) when studying patients with anxiety or fear-related disorders. [53] Different reinforcement schedules can also affect the magnitude and pattern of conditioned responses. [14] Finally, and particularly relevant for our study, the (f)MRI environment itself is stressful, which can alter both neural and behavioral responses. This stress may increase variability in the control group, potentially reducing statistical power to detect differences between patients and controls. [7, 54, 55]

Finally, it is also noteworthy that previous research suggests that fear-conditioning paradigms rely on partly distinct neural and cognitive mechanisms. Delay conditioning—especially in the rodent literature—primarily reflects amygdala-based associative learning. [56] Reversal learning additionally engages prefrontal and striatal circuits that support cognitive flexibility. [57] Finally, trace conditioning depends on hippocampal and working-memory processes to bridge the CS–US interval. [10] It is therefore plausible that anxiety-related alterations are more pronounced in basic associative learning, as observed in delay conditioning, whereas group differences in reversal or trace conditioning are less robust. [58]

Our study has several strengths and limitations. A key strength is our well-characterized patient sample, consisting of non-medicated adult individuals with a primary diagnosis of an anxiety disorder based on current classification systems and little-to-no comorbidity. These individuals were thoroughly phenotyped, exhibiting significantly higher anxiety symptom scores than controls across all psychometric measures. However, our sample was not entirely homogeneous, as it did not consist solely of patients with a single anxiety disorder (e.g. only GAD or SAD). Although GAD is currently classified as an anxiety disorder, it is often conceptualized not as a prototypical ‘fear disorder’ (like SAD) but rather as a ‘misery disorder,’ due to its strong associations with chronic negative affect and depression. [59] Additionally, some anxiety disorders (e.g., specific phobia, PD) were not represented. However, the prevailing assumption in the field is that fear learning alterations are a common feature across *all* anxiety disorders. [14, 46] Although our sample size was relatively small, the three paradigms examined—delay fear conditioning, fear reversal, and trace fear conditioning—elicited robust fear responses at the subjective, psychophysiological, and neural levels *within each group*. This indicates sufficient assay sensitivity, except for certain measures in the CS + 81 vs. CS + 50 contrast in trace conditioning. Moreover, for each process, we

included multiple operationalizations—such as all trials, early and late phases, and an alternative approach to fear reversal. However, there are numerous other possible ways to operationalize fear learning processes. [60] We were also unable to obtain valence and arousal ratings specifically for early versus late trials, as subjective ratings were collected only at the end of the task. Finally, another limitation concerns the interpretation of SCRs on non-reinforced trials. SCRs were quantified in a CS-locked time window on trials in which the unconditioned stimulus (UCS) was omitted, following common practice in human fear-conditioning research. However, classical psychophysiological work has shown that SCRs on non-reinforced trials may reflect not only conditioned responding to the CS, but also responses related to the omission of the expected UCS (i.e., third-interval responses). [61, 62] Accordingly, SCRs in the present study should be interpreted as an index of differential autonomic responding to CS+ versus CS−, rather than as a pure measure of conditioned responding in the strict psychophysiological sense. Future studies using interval-specific SCR modeling may help to further dissociate anticipatory and omission-related components of autonomic responses.

In summary, we did not find robust evidence that individuals with anxiety disorders (GAD and SAD) exhibit significant alterations in delay or trace fear conditioning or fear reversal, but they may be characterized by impaired safety learning. It is possible that other fear learning processes better characterize these disorders, or that such abnormalities are more relevant to other mental disorders. Future research should explore whether fear-learning abnormalities are more indicative of disorder severity rather than diagnostic status.

#### DATA AVAILABILITY

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

#### CODE AVAILABILITY

The code that supports the findings of this study is available from the corresponding author upon reasonable request.

#### REFERENCES

- Momen NC, Beck C, Lousdal ML, Agerbo E, McGrath JJ, Pedersen CB, et al. Mental health disorder trends in Denmark according to age, calendar period, and birth cohort. *JAMA psychiatry*. 2025;82:161–70.
- Craske MG, Stein MB, Eley TC, Milad MR, Holmes A, Rapee RM, et al. Anxiety disorders. *Nat Rev Dis Primers*. 2017;3:17024.
- Wu Y, Li X, Ji X, Ren W, Zhu Y, Chen Z, et al. Trends in the epidemiology of anxiety disorders from 1990–2021: a global, regional, and national analysis with a focus on the sociodemographic index. *J Affect Disord*. 2025;373:166–74.
- Alene KA, Al-Gheethi AAS, Alif SM, Andrei CL, Arkew M, Ashbaugh C, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet*. 2024;403:2133–61.
- Pittig A, Treanor M, LeBeau RT, Craske MG. The role of associative fear and avoidance learning in anxiety disorders: gaps and directions for future research. *Neurosci Biobehav Rev*. 2018;88:117–40.
- Schiller D, Levy I, Niv Y, LeDoux JE, Phelps EA. From fear to safety and back: reversal of fear in the human brain. *J Neurosci*. 2008;28:11517–25.
- Lonsdorf TB, Menz MM, Andreatta M, Fullana MA, Golkar A, Haaker J, et al. Don't fear 'fear conditioning': methodological considerations for the design and analysis of studies on human fear acquisition, extinction, and return of fear. *Neurosci Biobehav Rev*. 2017;77:247–85.
- Fullana MA, Harrison BJ, Soriano-Mas C, Vervliet B, Cardoner N, Ávila-Parcet A, et al. Neural signatures of human fear conditioning: an updated and extended meta-analysis of fMRI studies. *Mol Psychiatry*. 2016;21:500–8.
- Radua J, Savage HS, Vilajosana E, Jamieson A, Ablner B, Åhs F, et al. Neural correlates of human fear conditioning and sources of variability in 2199 individuals. *Nat Commun*. 2025;16:7869.
- Knight DC, Cheng DT, Smith CN, Stein EA, Helmstetter FJ. Neural substrates mediating human delay and trace fear conditioning. *J Neurosci*. 2004;24:218–28.
- Morris JS, Dolan RJ. Dissociable amygdala and orbitofrontal responses during reversal fear conditioning. *Neuroimage*. 2004;22:372–80.
- Craske MG, Kircanski K, Zelikowsky M, Mystkowski J, Chowdhury N, Baker A. Optimizing inhibitory learning during exposure therapy. *Behav Res Ther*. 2008;46:5–27.
- Craske MG, Treanor M, Conway CC, Zbozinek T, Vervliet B. Maximizing exposure therapy: an inhibitory learning approach. *Behav Res Ther*. 2014;58:10–23.
- Kausche FM, Carsten HP, Sobania KM, Riesel A. Fear and safety learning in anxiety- and stress-related disorders: an updated meta-analysis. *Neurosci Biobehav Rev*. 2025;169:105983.
- Roberts C, Apergis-Schoute AM, Bruhl A, Nowak M, Baldwin DS, Sahakian BJ, et al. Threat reversal learning and avoidance habits in generalised anxiety disorder. *Transl Psychiatry*. 2022;12:216–216.
- Heesbeen EJ, Bijlsma EY, Verdouw PM, van Lissa C, Hooijmans C, Groenink L. The effect of SSRIs on fear learning: a systematic review and meta-analysis. *Psychopharmacology*. 2023;240:2335–59.
- American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. 5th ed. Washington, DC: 2013.
- Savage HS, Davey CG, Fullana MA, Harrison BJ. Threat and safety reversal learning in social anxiety disorder - an fMRI study. *J Anxiety Disord*. 2020;76:102321.
- Lonsdorf TB, Merz CJ. More than just noise: Inter-individual differences in fear acquisition, extinction and return of fear in humans - Biological, experiential, temperamental factors, and methodological pitfalls. *Neurosci Biobehav Rev*. 2017;80:703–28.
- Yau JOY, McNally GP. The Rescorla-Wagner model, prediction error, and fear learning. *Neurobiol Learn Mem*. 2023;203:107799 <https://doi.org/10.1016/j.nlm.2023.107799>.
- Lissek S, Rabin SJ, McDowell DJ, Dvir S, Bradford DE, Geraci M, et al. Impaired discriminative fear-conditioning resulting from elevated fear responding to learned safety cues among individuals with panic disorder. *Behav Res Ther*. 2009;47:111–8.
- Cooper SE, Grillon C, Lissek S. Impaired discriminative fear conditioning during later training trials differentiates generalized anxiety disorder, but not panic disorder, from healthy control participants. *Compr Psychiatry*. 2018;85:84–93.
- Wehrli JM, Xia Y, Gerster S, Bach DR. Measuring human trace fear conditioning. *Psychophysiology*. 2022;59:e14119.
- Lissek S, Pine DS, Grillon C. The strong situation: a potential impediment to studying the psychobiology and pharmacology of anxiety disorders. *Biol Psychol*. 2006;72:265–70.
- Allen MT. Weaker situations: uncertainty reveals individual differences in learning: Implications for PTSD. *Cogn Affect Behav Neurosci*. 2023;23:869–93.
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry*. 1998;59:22–33.
- Savage HS, Davey CG, Fullana MA, Harrison BJ. Clarifying the neural substrates of threat and safety reversal learning in humans. *Neuroimage*. 2020;207:116427.
- Bradley MM, Lang PJ. Measuring emotion: the self-assessment manikin and the semantic differential. *J Behav Ther Exp Psychiatry*. 1994;25:49–59.
- Boucsein W, Fowles DC, Grimnes S, Ben-Shakhar G, Roth WT, Dawson ME, et al. Publication recommendations for electrodermal measurements. *Psychophysiology*. 2012;49:1017–34.
- Marin M-F, Zsido RG, Song H, Lasko NB, Killgore WDS, Rauch SL, et al. Skin conductance responses and neural activations during fear conditioning and extinction recall across anxiety disorders. *JAMA Psychiatry*. 2017;74:622–31.
- Pöhlchen D, Leuchs L, Binder FP, Blaskovich B, Nantawisarakul T, Topalidis P, et al. No robust differences in fear conditioning between patients with fear-related disorders and healthy controls. *Behav Res Ther*. 2020;129:103610.
- Hermann C, Ziegler S, Birbaumer N, Flor H. Psychophysiological and subjective indicators of aversive pavlovian conditioning in generalized social phobia. *Biol Psychiatry*. 2002;52:328–37.
- Michael T, Blechert J, Vriends N, Margraf J, Wilhelm FH. Fear conditioning in panic disorder: enhanced resistance to extinction. *J Abnorm Psychol*. 2007;116:612–7.
- Ahrens LM, Pauli P, Reif A, Mühlberger A, Langs G, Aalderink T, et al. Fear conditioning and stimulus generalization in patients with social anxiety disorder. *J Anxiety Disord*. 2016;44:36–46.
- Tinoco-González D, Fullana MA, Torrents-Rodas D, Bonillo A, Vervliet B, Blasco MJ, et al. Conditioned fear acquisition and generalization in generalized anxiety disorder. *Behav Ther*. 2015;46:627–39.
- Lissek S, Kaczurkin AN, Rabin S, Geraci M, Pine DS, Grillon C. Generalized anxiety disorder is associated with overgeneralization of classically conditioned fear. *Biol Psychiatry*. 2014;75:909–15.

37. Hermann A, Schäfer A, Walter B, Stark R, Vaitl D, Schienle A. Emotion regulation in spider phobia: role of the medial prefrontal cortex. *Soc Cogn Affect Neurosci*. 2009;4:257–67.
38. Brandl F, Le Houcq Corbi Z, Mulej Bratec S, Sorg C. Cognitive reward control recruits medial and lateral frontal cortices, which are also involved in cognitive emotion regulation: a coordinate-based meta-analysis of fMRI studies. *NeuroImage*. 2019;200:659–73.
39. Bo K, Kraynak TE, Kwon M, Sun M, Gianaros PJ, Wager TD. A systems identification approach using bayes factors to deconstruct the brain bases of emotion regulation. *Nat Neurosci*. 2024;27:975–87.
40. Lau JY, Britton JC, Nelson EE, Angold A, Ernst M, Goldwin M, et al. Distinct neural signatures of threat learning in adolescents and adults. *Proc Natl Acad Sci*. 2011;108:4500–5.
41. Roesmann K, Toelle J, Johanna Leehr E, Wessing I, Böhnlein J, Seeger F, et al. Neural correlates of fear conditioning are associated with treatment-outcomes to behavioral exposure in spider phobia - evidence from magnetoencephalography. *Neuroimage Clin*. 2022;35:103046.
42. Morriss J, Hoare S, van Reekum CM. It's time: a commentary on fear extinction in the human brain using fMRI. *Neurosci Biobehav Rev*. 2018;94:321–2.
43. Savage HS, Davey CG, Fullana MA, Harrison BJ. Threat and safety reversal learning in social anxiety disorder – an fMRI study. *J Anxiety Disord*. 2020;76:102321.
44. Apergis-Schoute AM, Gillan CM, Fineberg NA, Fernandez-Egea E, Sahakian BJ, Robbins TW. Neural basis of impaired safety signaling in obsessive compulsive disorder. *Proc Natl Acad Sci USA*. 2017;114:3216–21.
45. Milad MR, Quirk GJ. Fear extinction as a model for translational neuroscience: ten years of progress. *Annu Rev Psychol*. 2012;63:129–51.
46. Cooper SE, van Dis EAM, Hagensars MA, Kryptos A-M, Nemeroff CB, Lissek S, et al. A meta-analysis of conditioned fear generalization in anxiety-related disorders. *Neuropsychopharmacology*. 2022;47:1652–61.
47. World Health Organization. International statistical classification of diseases and related health problems. 11th ed. 2019.
48. Marquand AF, Rezek I, Buitelaar J, Beckmann CF. Understanding heterogeneity in clinical cohorts using normative models: beyond case-control studies. *Biol Psychiatry*. 2016;80:552–61.
49. Suarez-Jimenez B, Albajes-Eizaguirre A, Lazarov A, Zhu X, Harrison BJ, Radua J, et al. Neural signatures of conditioning, extinction learning, and extinction recall in posttraumatic stress disorder: a meta-analysis of functional magnetic resonance imaging studies. *Psychol Med*. 2020;50:1442–51.
50. Weingarden H, Renshaw KD, Wilhelm S, Tangney JP, DiMauro J. Anxiety and shame as risk factors for depression, suicidality, and functional impairment in body dysmorphic disorder and obsessive compulsive disorder. *J Nerv Ment Dis*. 2016;204:832–9.
51. Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. *Am J Psychiatry*. 2005;162:1171–8.
52. Tuominen L, Romaniuk L, Milad MR, Goff DC, Hall J, Holt DJ. Impairment in acquisition of conditioned fear in schizophrenia. *Neuropsychopharmacology*. 2022;47:681–6.
53. Ney LJ, Luck CC, Waters AM, Lipp OV. Conditional stimulus choices affect fear learning: comparing fear conditioning with neutral faces and shapes or angry faces. *Psychophysiology*. 2022;59:e14068 <https://doi.org/10.1111/psyp.14068>.
54. Weldon AL, Hagan M, Van Meter A, Jacobs RH, Kassel MT, Hazlett KE, et al. Stress response to the functional magnetic resonance imaging environment in healthy adults relates to the degree of limbic reactivity during emotion processing. *Neuropsychobiology*. 2015;71:85–96.
55. Mutschler I, Wieckhorst B, Meyer AH, Schweizer T, Klarhöfer M, Wilhelm FH, et al. Who gets afraid in the MRI-scanner? neurogenetics of state-anxiety changes during an fMRI experiment. *Neurosci Lett*. 2014;583:81–86.
56. LeDoux JE. Emotion Circuits in the Brain. *Annu Rev Neurosci*. 2000;23:155–84.
57. Schiller D, Delgado MR. Overlapping neural systems mediating extinction, reversal and regulation of fear. *Trends Cogn Sci*. 2010;14:268–76.
58. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. *Am J Psychiatry*. 2007;164:1476–88.
59. Clark LA, Watson D. Distress and fear disorders: an alternative empirically based taxonomy of the 'mood' and 'anxiety' disorders. *Br J Psychiatry*. 2006;189:481–3.
60. Lonsdorf TB, Gerlicher A, Klingelhöfer-Jens M, Kryptos A-M. Multiverse analyses in fear conditioning research. *Behav Res Ther*. 2022;153:104072.
61. Öhman A. The orienting response during Pavlovian conditioning. In: Siddle D (ed). *Orienting and habituation: Perspectives in human research*. New York: Wiley;1983. pp 315–69.

62. Dawson ME, Schell AM, Filion DL. The electrodermal system. *Handb Psychophysiol*. 2007;2:200–23.

## ACKNOWLEDGEMENTS

J.R., C.S.M and M.A.F. have received support from the Spanish Ministry of Science and Innovation as part of the Plan Nacional de I + D + I and co-financed by the Instituto de Salud Carlos III (ISCIII) – Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) [P116/00144, P116/00889, P119/01171, P122/00261, P119/00272]. C.S.M. and M.A.F. have received support from the Agencia Estatal de Investigación (PID2022-139081OB-C21; PID2022-139081OB-C22) financed by MICIU/AEI /10.13039/501100011033, and FEDER, UE. A.S. has received support from National Institutes of Health (AA030042, AA031261, MH131264, MH121409, MH126426) and University of Maryland. C.S.M. has received support from the Marató TV3 foundation (202201 30 31 32 33). J.R. and C.S.M. have received support from Agència de Gestió d'Ajuts Universitaris i de Recerca [2021SGR01017, 2021SGR1128]. S.B. was supported by #NEXTGENERATIONEU (NGEU) and funded by the Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), and project MNESYS (PE0000006) - a multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553, October 11, 2022) and Bial Foundation, Portugal (235/22).

## AUTHOR CONTRIBUTIONS

EV, SB: Data curation, Formal analysis, Methodology, Writing - Review & Editing; PCE, IMZ, AJS, C-SM, VDP: Data curation, Formal analysis, Writing - Review & Editing; AJSS: Conceptualization, Writing - Review & Editing; JR: Formal analysis, Methodology; Writing - Review & Editing; MAF, CSM: Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Supervision, Writing - Original Draft, Writing - Review & Editing.

## COMPETING INTERESTS

The authors declare no competing interests.

## ETHICS APPROVAL

The study was approved by the ethics committee at Hospital de Bellvitge in Barcelona (protocol # PR144/16). All participants provided informed written consent prior to participating.

## ADDITIONAL INFORMATION

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41398-026-03996-6>.

**Correspondence** and requests for materials should be addressed to Miquel A. Fullana.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026

1 ***Fear learning in unmedicated patients with anxiety disorders: a comparison of delay***  
2 ***conditioning, fear reversal, and trace conditioning.***

3

4 Supplementary Material

**Page**

**Supplementary Methods**

**Recruitment procedures** 2

**Self-report measures** 2

**Fear learning assessment** 3

Instructions

Unconditioned stimuli

Conditioned stimuli

**Measures of conditioned fear** 3

Subjective ratings

Skin conductance responses

    Data acquisition

    Data processing and missingness

Brain activation

    Imaging acquisition

    Anatomical data (pre)processing

    Functional data (pre)preprocessing

**Pre-conditioning analyses** 5

**Additional analyses** 5

    Early and late

    Fear reversal – threat and safety reversal

**Supplementary Tables** 7

**Supplementary Figures** 33

**Supplementary References** 36

5

6

## 7 **SUPPLEMENTARY METHODS**

### 9 **Recruitment procedures**

10  
11 We screened a large number ( $n = 840$ ) of adult individuals (age  $\geq 18$ ) from the university community,  
12 including students and staff, using the Spanish version <sup>1</sup> of the State-Trait Anxiety Inventory–Trait  
13 (STAI-T) subscale <sup>2</sup> via a secure web system. We aimed to recruit participants with different levels of  
14 trait anxiety (including individuals with a current anxiety disorder). Therefore, STAI-T data were  
15 stratified into quartiles, and individuals who met preliminary inclusion criteria were selected from each  
16 stratum. These individuals ( $n = 361$ ) were assessed during a telephone interview by an experienced  
17 clinician who administered the Spanish version <sup>3</sup> of the Mini International Neuropsychiatric Interview <sup>4</sup>  
18 and confirmed that potential participants fulfilled the inclusion/exclusion criteria. Inclusion criteria  
19 were: 1) age between 18 and 36 years, 2) owning a smartphone (because the larger study included  
20 smartphone-based assessments), and 3) being willing to participate in a neuroimaging assessment.  
21 Exclusion criteria were 1) current or previous severe medical disorder or current medication that could  
22 interfere with the study objectives (as per self-report), 2) current or past mental disorder (except  
23 current anxiety disorder, see below), or 3) current substance use (except occasional use of alcohol  
24 and other recreational drugs, or tobacco), as per the MINI, and 4) any contraindication to  
25 neuroimaging assessment. Those who met the inclusion/exclusion criteria ( $n = 206$ ) gave written  
26 informed consent and participated in the laboratory session reported in this manuscript. Twenty-seven  
27 participants were excluded from MRI analysis (5 because of incidental findings, and 22 due to motion  
28 artifacts or poor image quality), leaving 179 potential participants. Thirty-four of these 179 participants  
29 were given a diagnosis of a current anxiety disorder and made up the patient group. Among the rest  
30 ( $n = 135$ ), and to enhance statistical power, we selected 3 controls for each patient, ensuring that the  
31 samples had a matched gender distribution (55.9% female) and no statistically significant differences  
32 in age (mean age 25.6 years in both,  $p = 1$ ). These participants ( $n = 102$ ) made up the control group.

33 For the fMRI analyses of the trace conditioning task, three patients and nine controls were  
34 excluded due to poor data quality. Additionally, for the SCR analyses, one patient and four controls  
35 were excluded from the delay/reversal fear-conditioning task due to recording artifacts, and four  
36 patients and eight controls were excluded from the trace conditioning task for the same reason. The  
37 final number of participants included in each analysis/task is shown in **Sup. Table 1**.

### 39 **Self-report measures**

40 Participants completed the Spanish versions of the following measures:

41 -Trait subscale of the *State-Trait Anxiety Inventory* (STAI-T) a 20-item questionnaire assessing trait  
42 anxiety (dispositional negative affect). <sup>1,2</sup> Total scores range from 0 to 60.

43 -*Intolerance of Uncertainty Scale* (IUS), a 27-item questionnaire assessing the tendency to react  
44 negatively to uncertain situations. <sup>5,6</sup> Total scores range from 0 to 135.

45 -*Liebowitz Social Anxiety Scale (LSAS)*, a 24-item questionnaire assessing anxiety and avoidance of  
46 social situations.<sup>7,8</sup> Total scores range from 0 to 144.

47 -*Screening scale for DSM-IV Generalized Anxiety Disorder*, a 12-item questionnaire assessing  
48 Generalized Anxiety Disorder symptoms.<sup>9,10</sup> Total scores range from 0 to 12.

49 -*Penn State Worry Questionnaire-11 (PSWQ-11)* a 11-item questionnaire assessing trait worry.<sup>11,12</sup>  
50 Total scores range from 11 to 55.

51 -*Depression, Anxiety and Stress Scales (DASS-21)* a 21-item scale assessing depression, anxiety, and  
52 stress symptoms.<sup>13,14</sup> Total scores range from 0 to 21 for each subscale.

53

#### 54 **Fear learning assessment**

##### 55 **Instructions**

56 Before starting the tasks (outside the scanner), participants were informed that they would, at some  
57 point during the session, view geometrical figures and experience electric shocks. They were also  
58 familiarized with the system used for recording subjective ratings.

59

##### 60 **Unconditioned stimuli**

61 The two unconditioned stimuli (USs) were brief electric shocks, delivered as a quadratic pulse for the  
62 delay acquisition/reversal task and a sinusoidal pulse for the trace task. Shocks were administered via  
63 two MRI-compatible Ag/AgCl electrodes filled with electrolyte gel and delivered using a Biopac  
64 STMISSOLA stimulator. Electrodes were placed on the left hand for the delay acquisition/reversal task  
65 and on the left forearm for the trace task. Delivering shocks to different locations helped minimize  
66 carryover or generalization effects between tasks. The intensity of both USs was individually  
67 calibrated inside the scanner using a staircase procedure to ensure the shocks were unpleasant but  
68 not painful (rated >7 on a 1–10 aversiveness scale, where 10 was maximum aversiveness). The  
69 procedure began at 30V, increasing in 10V increments until the participant indicated their maximum  
70 level of discomfort or the 100V maximum was reached.

71

72

##### 73 **Measures of conditioned fear**

##### 74 **Subjective ratings**

75 For the valence ratings, participants responded to the question "How unpleasant/pleasant did you find  
76 the [colour of the CS] sphere?". Responses ranged from 1='very unpleasant' to 5='very pleasant'. For  
77 anxious arousal ratings, participants responded to the question: "How anxious did the [colour of the  
78 CS] sphere make you feel?". Responses ranged from 1='not anxious' to 5='very anxious'. Participants'  
79 ratings were recorded using an MRI-compatible, three-button fiber-optic response box (Lumina 3G  
80 Controller, Cedrus Corporation), with which participants were familiarized prior to scanning

## 81 **Skin conductance responses**

82 *Data acquisition.* Skin conductance data were continuously acquired during both fear conditioning  
83 tasks using a Biopac EDA100c module, MP150 Amplifier, and AcqKnowledge 4.4.0 software (250-Hz  
84 sampling, 5  $\mu$ Siemens/Volt gain, 10-Hz low-pass, DC high-pass). Skin conductance was collected  
85 from the volar surfaces of the distal phalanges of the third and fourth fingers of the left hand, using  
86 two Ag-AgCl, nonpolarizable electrodes and isotonic gel (GEL101).

87 *Data processing and missingness.* Data preprocessing was implemented using AcqKnowledge. Data  
88 were down-sampled (62.5 Hz) and smoothed to mitigate movement artifacts (63-sample median and  
89 1-Hz low-pass filters). All SCRs were visually inspected. Trial-by-trial SCRs were quantified using  
90 custom-made MATLAB scripts as trough-to-peak responses with an onset latency of 1-6 s in the  
91 delay/reversal task and 1-5.3 s in the trace task. Trials with increases  $<0.02 \mu$ S or that lasted  $<0.5$  s  
92 were scored as non-responses and set to a value of 0  $\mu$ S. Trials with artifacts or excessive baseline  
93 activity were treated as missing responses. Using SCR raw data, participants showing non-valid  
94 responses in  $\geq 75\%$  of the CS trials followed by a US during delay conditioning or trace conditioning  
95 were classified as physiological non-responders and all SCR trials treated as missing responses. After  
96 excluding physiological non-responders, SCR amplitudes were normalized and range corrected  
97 separately for each task using the formula  $\ln(1+ \text{SCR})/\ln(1 + \text{MAX})$ , where MAX was the individual's  
98 maximum response to the US.

99

## 100 **Brain activation**

101 *Imaging Acquisition.* T1-weighted (T1w) anatomical scans were acquired using a three-dimensional  
102 fast-spoiled gradient, inversion-recovery sequence (TR=10.43 ms; TE=4.8 ms; flip=8°; slice  
103 thickness=0.75 mm; in-plane=0.75  $\times$  0.75 mm; matrix=320  $\times$  320; field-of-view=240  $\times$  240). Functional  
104 data were acquired using a single-shot gradient-echo echo-planar imaging (EPI) sequence (TR=2,000  
105 ms; TE=25 ms; flip=90°; slice thickness=3 mm; in-plane resolution=3  $\times$  3 mm; matrix=80  $\times$  80).  
106 Images were collected in the AC-PC plane to minimize potential susceptibility artifacts. For the delay  
107 fear conditioning task, one run comprising 480 volumes was acquired (total acquisition time: 15m  
108 25s). For the trace conditioning task, one run of 458 volumes was collected (total acquisition time:  
109 14m 13s)

110 *Anatomical data (pre)processing.* T1w images were corrected for intensity non-uniformity using the  
111 ANTs (version 2.2.0.6) N4BiasFieldCorrection algorithm,<sup>15</sup> skull-stripped using a Nipype  
112 implementation of antsBrainExtraction.sh and the OASIS30ANTs as a target template, and  
113 segmented using the FSL (version 5.0.9 7)<sup>16</sup> fast algorithm. Brain surfaces were reconstructed using  
114 the FreeSurfer (version 6.0.1 8)<sup>17</sup> recon-all algorithm. Brain masks were refined using a variant of a  
115 previously described method for reconciling ANTs and FreeSurfer gray matter (GM) segments.<sup>18</sup>  
116 Volume-based spatial normalization to two standard brain-extracted templates

117 (MNI152NLin2009cAsym and MNI152NLin6Asym)<sup>19</sup> was performed using the ANTs diffeomorphic  
118 algorithm.

119 *Functional data (pre)processing.* fMRI data were preprocessed using fMRIPrep 1.4.1,<sup>20</sup> which is  
120 based on Nipype 1.2.0.<sup>21</sup> Preprocessing included skull stripping, susceptibility distortion correction  
121 using field maps, and co-registration of each BOLD reference image to the participant's T1-weighted  
122 anatomical scan using boundary-based registration (bbrregister, FreeSurfer).<sup>22</sup> Slice timing correction  
123 was applied using AFNI's 3dTshift,<sup>23</sup> and motion correction was performed with FSL's mcflirt.<sup>24</sup> All  
124 transformations (motion correction, distortion correction, co-registration, and spatial normalization)  
125 were combined and applied in a single resampling step using ANTs with Lanczos interpolation.<sup>25</sup> The  
126 resulting BOLD time-series were normalized to MNI152NLin2009cAsym space and spatially  
127 smoothed with a 6 mm FWHM Gaussian kernel. For denoising, ICA-AROMA was used to identify and  
128 remove motion-related components;<sup>26</sup> the analyses reported here used the non-aggressively  
129 denoised time-series. Nuisance regressors included six motion parameters, their temporal derivatives  
130 and quadratic terms, as well as anatomical and temporal CompCor components.<sup>27</sup> These were  
131 computed after high-pass filtering (128 s cutoff), and the number of retained components was set to  
132 explain at least 50% of variance within the respective noise masks (white matter, CSF, or combined).  
133 Framewise displacement (FD) and DVARS were computed for each run. Volumes exceeding 0.5 mm  
134 FD or 1.5 standardized DVARS were flagged as motion outliers and excluded from first-level  
135 analyses.<sup>28</sup> Unless otherwise stated, all analyses were conducted in MNI space using the 6 mm  
136 smoothed, non-aggressively denoised BOLD time-series.

137

### 138 **Pre-conditioning analysis**

139 Differences between responses to each to-be CS within each group were assessed using a paired t-  
140 test for the delay/reversal task (CS+ and CS-), and one-way repeated measures ANOVAs for the  
141 trace task (CS-, CS+50, and CS+81). Specifically, we compared the last CS trial during  
142 preconditioning for SCR and brain activation, as well as arousal and valence ratings collected after  
143 the preconditioning phase.

144

### 145 **Additional Analyses**

146 Fear reversal – threat and safety reversal

147 For subjective ratings, we defined threat reversal as the difference between arousal or valence ratings  
148 for the CS+ during reversal ("new CS+") and the CS- during conditioning. Safety reversal was defined  
149 as the difference between arousal or valence ratings for the CS- during reversal ("new CS-") and the  
150 CS+ during conditioning. For SCR, threat reversal was operationalized as the sum of all SCR  
151 responses to the unreinforced new CS+ (CS+ during reversal, 10 trials) minus the sum of responses  
152 to the CS- during conditioning. Similarly, safety reversal was defined as the sum of all SCR  
153 responses to the new CS- (CS- during reversal) minus the sum of responses to unreinforced CS+

154 during conditioning (10 trials). For fMRI analyses, first-level contrast images were generated by  
155 comparing new CS+ vs. CS- for threat reversal and new CS- vs. CS+ for safety reversal. Both  
156 contrasts used the same trials as the SCR analysis. Threat and safety reversal for subjective ratings  
157 and SCR were analyzed separately using two sample t-tests to compare controls and patients. fMRI  
158 group differences for each contrast were assessed using two-sample t-tests.

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182 **SUPPLEMENTARY TABLES**

183 **Supplementary Table 1.** Number of participants included in each analysis

	Delay /Reversal task		Trace task	
	Healthy controls	Patients	Healthy controls	Patients
fMRI analysis	102	34	93	31
SCR analysis	98	33	94	30

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201 **Supplementary Table 2.** Paired t-test results for the effects of CS type on SCR, arousal, and valence  
202 during preconditioning of the delay fear-conditioning task.

Effect	t-test	<i>t</i>	<i>df</i>	<i>p</i>
Healthy Controls	SCR	0.44	95	.661
	Arousal ratings	0.58	95	.566
	Valence ratings	0.65	95	.517
Patients	SCR	-0.89	32	.377
	Arousal ratings	0.24	32	.812
	Valence ratings	-0.37	32	.712

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220 **Supplementary Table 3.** ANOVAs results for the effects CS type on SCR, arousal, and valence during  
 221 preconditioning of the trace fear-conditioning task.

Group	ANOVA	<i>F</i>	<i>df</i>	<i>p</i>	$\eta^2$
Healthy Controls	SCR	7.06	2, 186	.001	<.05
	Arousal ratings	0.48	2, 186	.606	<.01
	Valence ratings	1.72	2, 186	.182	<.01
Patients	SCR	0.77	2, 58	.467	<.01
	Arousal ratings	1.39	2, 58	.163	<.05
	Valence ratings	1.87	2, 58	.256	<.05

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239 **Supplementary Table 4.** ANOVAs results for the effects of group and CS type on SCR, arousal, and  
 240 valence during delay conditioning

ANOVA	Effect	<i>F</i>	<i>df</i>	<i>p</i>	$\eta^2$
SCR	G	6.20	1, 127	.014	.047
	CS	72.64	1, 127	<.001	.364
	CS x G	0.33	1, 127	.566	.003
Arousal ratings	G	1.91	1, 127	.169	.015
	CS	278.53	1, 127	<.001	.687
	CS x G	0.34	1, 127	.560	.003
Valence ratings	G	.004	1, 127	.837	<.001
	CS	273.56	1, 127	<.001	.683
	CS x G	0.26	1, 127	.609	.002

241 *Note:* G = Group; CS = CS type

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257 **Supplementary Table 5.** ANOVA results for the effects of group, CS type, and phase (early and late)  
 258 on SCR during delay fear conditioning.

Effect	<i>F</i>	<i>df</i>	<i>p</i>	$\eta^2$
G	6.20	1, 127	.014	.047
P	28.22	1, 127	<.001	.182
P x G	1.92	1, 127	.168	.015
CS	72.64	1, 127	<.001	.364
CS x G	0.33	1, 127	.566	.003
P x CS	18.18	1, 127	<.001	.125
P x CS x G	4.18	1, 127	.043	.032

259 *Note:* G = Group, P = Phase, CS = CS type

260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283

284 **Supplementary Table 6.** Brain activations during delay fear conditioning (CS+>CS-) for healthy  
 285 controls.

286  
 287

AAL Region	Cluster <i>p</i> value - FWER	N voxels	<i>t</i>	MNI (x,y,z)	Peak <i>p</i> value uncorrected
SupraMarginal_R	<0.001	255	8.85	63, -36, 30	<0.001
			7.38	54, -30, 30	<0.001
			6.82	63, -21, 21	<0.001
SupraMarginal_L	<0.001	162	7.96	-63, -39, 30	<0.001
			6.46	-66, -24, 27	<0.001
			5.99	-60, -24, 21	<0.001
Insula_R	<0.001	189	7.55	48, 18, -3	<0.001
			7.09	57, 15, 3	<0.001
			6.5	33, 27, 0	<0.001
Thalamus_R	<0.001	163	7.38	9, -18, -3	<0.001
			7.11	18, -18, 9	<0.001
			6.68	9, -18, 9	<0.001
Temporal_Sup_R	<0.001	18	7	48, -24, -3	<0.001
Cingulum_Mid	<0.001	182	6.79	0, 6, 42	<0.001
			6.75	-6, 12, 39	<0.001
			6.5	3, 3, 60	<0.001
Rolandic_Oper_L	<0.001	62	6.77	-57, 3, 3	<0.001
			6.49	-51, 9, -3	<0.001
			5.45	-40, 19, -2	<0.001
Cerebelum_6_L	<0.001	19	6.32	-30, -63, -21	<0.001
Thalamus_L	<0.001	33	6.31	-15, -12, 9	<0.001
			5.76	-6, -9, 9	<0.001
Cerebelum_6_R	<0.001	11	6.19	36, -57, -27	<0.001
			5.61	30, -63, -24	<0.001

288 *Note:* AAL = Automated Anatomical Labeling, FWER = Family Wise Error Rate, N = Number, MNI =  
 289 Montreal Neurological Institute

290  
 291  
 292  
 293  
 294  
 295

296 **Supplementary Table 7.** Brain activations during delay fear conditioning (CS+ vs. CS-) for patients  
 297 with anxiety disorders.

AAL Region	Cluster <i>p</i> value FWER	N voxels	<i>t</i>	MNI (x,y,z)	Peak <i>p</i> value uncorrected
SupraMarginal_R	<0.001	273	6.22	66, -39, 30	<0.001
			5.47	66, -30, 39	<0.001
			5.23	66, -27, 27	<0.001
Cingulum_Ant	<0.001	466	5.26	-3, 24, 27	<0.001
			4.65	3, 9, 33	<0.001
Cingulum_Mid	<0.001	466	4.41	6, 9, 54	<0.001
			4.91	57, 12, -3	<0.001
			4.29	39, 30, -6	<0.001
Temporal_Pole_Sup_R	<0.001	269	4.26	45, 9, 0	<0.001
			4.35	-45, 12, -6	<0.001
Insula_R	<0.001	171	4.1	-36, 6, 6	<0.001
			3.76	-54, 9, 12	<0.001

298 *Note:* AAL = Automated Anatomical Labeling, FWER = Family Wise Error Rate, N = Number, MNI =  
 299 Montreal Neurological Institute

300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311

312 **Supplementary Table 8.** ANOVAs results for the effects of group and CS type on SCR, arousal, and  
 313 valence during fear reversal.

ANOVA	Effect	<i>F</i>	<i>df</i>	<i>p</i>	$\eta^2$
SCR	G	1.79	1, 127	.184	.014
	CS	87.19	1, 127	<.001	.683
	CS x G	0.80	1, 127	.371	.006
Arousal ratings	G	3.10	1, 127	.081	.024
	CS	221.59	1, 127	<.001	.636
	CS x G	2.22	1, 127	.138	.017
Valence ratings	G	0.72	1, 127	.395	.006
	CS	165.94	1, 127	<.001	.566
	CS x G	1.07	1, 127	.303	.008

314 *Note:* G = Group; CS = CS type

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330 **Supplementary Table 9.** ANOVA results for the effects of group, CS type, and phase on SCR during  
331 fear reversal.

Effect	<i>F</i>	<i>df</i>	<i>p</i>	$\eta^2$
G	1.79	1, 127	.184	.014
P	46.64	1, 127	<.001	.269
P x G	1.43	1, 127	.233	.011
CS	87.19	1, 127	<.001	.407
CS x G	0.80	1, 127	.372	.006
P x CS	0.45	1, 127	.502	.004
P x CS x G	0.01	1, 127	.909	.000

332 Note: *G* = Group, *P* = Phase, CS = CS type

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347 **Supplementary Table 10.** Brain activations during fear reversal (new CS+ vs. new CS-) for healthy  
 348 controls.

AAL Region	Cluster <i>p</i> value FWER	N voxels	<i>t</i>	MNI (x,y,z)	Peak <i>p</i> value uncorrected
SupraMarginal_R	<0.001	116	7.27	60, -30, 30	<0.001
SupraMarginal_L	<0.001	60	6.33	-66, -36, 24	<0.001
			4.78	-63, -24, 24	<0.001
Temporal_Pole_Sup_L	<0.001	41	6.31	-60, 9, 0	<0.001
Temporal_Pole_Sup_R	<0.001	146	6.07	57, 12, 0	<0.001
Insula_R			6.03	36, 24, 6	<0.001
			5.91	36, 15, 6	<0.001
Cingulum_Mid	<0.001	70	6	3, 18, 36	<0.001
			5.66	0, 3, 42	<0.001

349 *Note:* AAL = Automated Anatomical Labeling, FWER = Family Wise Error Rate, N = Number, MNI =  
 350 Montreal Neurological Institute

351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364

365 **Supplementary Table 11.** Brain activations during fear reversal (new CS+ vs. new CS-) for patients  
 366 with anxiety disorders.

AAL Region	Cluster $p$ value FWER	N voxels	$t$	MNI (x,y,z)	Peak $p$ value uncorrected
SupraMarginal_R	<0.01	139	5.67	57, -33, 33	<0.001
			4.73	63, -30, 27	<0.001
			3.86	54, -21, 24	<0.001
SupraMarginal_L	<0.001	178	5.01	-57, -42, 33	<0.001
			4.2	-63, -39, 39	<0.001
			3.65	-66, -27, 18	<0.001
Insula_R	<0.001	197	4.8	45, 3, 9	<0.001
			4.69	60, 9, -3	<0.001
			4.35	36, 27, 9	<0.001
Temporal_Pole_Sup_L	<0.001	184	4.72	-60, 12, -6	<0.001
			4.25	-60, 3, 3	<0.001
			4.22	-57, 9, 9	<0.001
Thalamus	<0.05	93	4.39	3, -6, 9	<0.001
			4.22	-3, -24, 6	<0.001
			3.5	-12, -6, 12	<0.001

367 *Note:* AAL = Automated Anatomical Labeling, FWER = Family Wise Error Rate, N = Number, MNI =  
 368 Montreal Neurological Institute

369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379

380 **Supplementary Table 12.** T-test results on SCR, arousal and valence for the comparison of threat  
 381 reversal (new CS+ vs. CS-) and safety reversal (new CS- vs. CS+) between healthy controls and  
 382 patients with anxiety disorders.

	Measure	<i>t</i>	<i>df</i>	<i>p</i>	Cohen's <i>d</i>
	SCR	1.429	127	.155	0.2884
Threat reversal	Valence	1.400	127	.164	0.2824
	Arousal	-1.466	127	.145	-0.2957
	SCR	1.373	127	.172	0.2770
Safety reversal	Valence	-0.216	127	.829	-0.0436
	Arousal	0.497	127	.620	0.1003

383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397

398 **Supplementary Table 13.** ANOVAs results for the effects of group and CS type on SCR, arousal and  
 399 valence during trace conditioning

ANOVA	Effect	<i>F</i>	<i>df</i>	<i>p</i>	$\eta^2$
SCR	G	<.01	1, 122	.963	<.001
	CS <sup>a</sup>	45.13	1.46, 178.4	<.001	.270
	CS X G <sup>a</sup>	<.001	1.46, 178.4	.997	<.001
Arousal ratings	G	3.47	1, 122	.065	.028
	CS <sup>b</sup>	127.83	1.88, 229.47	<.001	.512
	CS X G <sup>b</sup>	2.26	1.88, 229.47	.110	.018
Valence ratings	G	0.15	1, 122	.699	.001
	CS <sup>c</sup>	111.68	1.69, 205.62	<.001	.478
	CS X G <sup>c</sup>	1.84	1.69, 205.62	.167	.015

400 *Note:* G = Group; CS = CS type. Greenhouse-Geisser corrected values identified with lowercase letters.  
 401 <sup>a</sup>: Mauchly's *W* = .632, *p* < .001, Greenhouse-Geisser  $\epsilon$  = .731  
 402 <sup>b</sup>: Mauchly's *W* = .937, *p* = .019, Greenhouse-Geisser  $\epsilon$  = .940  
 403 <sup>c</sup>: Mauchly's *W* = .813, *p* < .001, Greenhouse-Geisser  $\epsilon$  = .843

404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416

417 **Supplementary Table 14.** ANOVA results for the effects of group, CS type, and phase on SCR during  
 418 trace fear conditioning.

Effect	<i>F</i>	<i>df</i>	<i>p</i>	$\eta^2$
G	0.01	1, 122	.963	.000
P	76.83	1, 122	<.001	.386
P x G	0.39	1, 122	.533	.003
CS <sup>a</sup>	45.13	1.46, 178.40	<.001	.270
CS x G <sup>a</sup>	0.00	1.46, 178.40	.997	.000
P x CS <sup>b</sup>	6.87	1.83, 222.98	.002	.053
P x CS x G <sup>b</sup>	0.66	1.83, 222.98	.506	.005

419 *Note:* G = Group, P = Phase, CS = CS type. Greenhouse-Geisser corrected values identified with  
 420 lowercase letters.

421 <sup>a</sup>: Mauchly's *W* = .632, *p* < .001, Greenhouse-Geisser  $\epsilon$  = .731

422 <sup>b</sup>: Mauchly's *W* = .906, *p* = .003, Greenhouse-Geisser  $\epsilon$  = .914

423

424 **Supplementary Table 15.** Brain activations during trace fear conditioning (CS50+ vs. CS-) for healthy  
 425 controls.

AAL Region	Cluster $p$ value FWER	N voxels	$t$	MNI (x,y,z)	Peak $p$ value uncorrected
Thalamus	<0.001	191	9.32	6, -21, -3	<0.001
			7.09	-6, -21, -3	<0.001
			6.34	12, -18, 6	<0.001
Supp_Motor_Area	<0.001	609	7.86	-9, -9, 69	<0.001
			7.72	9, -6, 69	<0.001
			7.58	6, 3, 51	<0.001
Precentral_L	<0.001	188	7.67	-42, -6, 51	<0.001
			6.3	-36, -18, 42	<0.001
			4.8	-51, 0, 42	<0.001
SupraMarginal_L	<0.001	193	7.2	-51, -33, 27	<0.001
			6.11	-57, -39, 33	<0.001
			5.96	-60, -21, 24	<0.001
Postcentral_R	<0.001	49	6.07	30, -27, 66	<0.001
			6.02	27, -27, 57	<0.001
Insula_L	<0.001	50	5.71	-33, 27, 3	<0.001
			5.63	-33, 18, 9	<0.001
Frontal_Mid_R	<0.001	23	5.65	45, -3, 54	<0.001

426 *Note:* AAL = Automated Anatomical Labeling, FWER = Family Wise Error Rate, N = Number, MNI =  
 427 Montreal Neurological Institute

428

429

430

431

432

433

434

435

436

437 **Supplementary Table 16.** Brain activations during trace fear conditioning (CS50+ vs. CS-) for patients  
 438 with anxiety disorders.

AAL Region	Cluster <i>p</i> value FWER	N voxels	<i>t</i>	MNI (x,y,z)	Peak <i>p</i> value uncorrected
Cingulum_Mid_R	<0.001	285	7.71	9, -27, 51	<0.001
Postcentral_R			5.56	30, -30, 60	<0.001
			4.94	24, -36, 60	<0.001
Supp_Motor_Area_R	<0.001	583	6.94	3, -6, 60	<0.001
			6.06	3, 0, 72	<0.001
			5.86	9, 6, 57	<0.001
Precentral_L	<0.001	153	6.52	-36, -6, 48	<0.001
			5.68	-45, -6, 51	<0.001
			5.2	-51, 3, 42	<0.001
SupraMarginal_L	<0.001	141	6.25	-63, -27, 21	<0.001
			4.86	-60, -18, 21	<0.001
			4.5	-54, -42, 39	<0.001
Fusiform_R	<0.001	292	5.75	36, -75, -15	<0.001
			5.66	36, -84, -12	<0.001
			5.23	-6, -87, 3	<0.001
SupraMarginal_R	<0.001	109	5.67	54, -27, 24	<0.001
			4.58	48, -15, 18	<0.001
			3.67	60, -39, 27	<0.001
Frontal_Inf_Oper_L	<0.001	247	5.48	-57, 9, 15	<0.001
			5.14	-51, 0, 6	<0.001
Insula_L			5.01	-42, 18, 0	<0.001
Insula_R	<0.05	59	5.18	36, 24, 0	<0.001
Frontal_Inf_Oper_R	<0.05	46	4.73	54, 15, 0	<0.001
			4.42	51, 6, 0	<0.001
			3.99	48, 0, 6	<0.001

439 *Note:* AAL = Automated Anatomical Labeling, FWER = Family Wise Error Rate, N = Number, MNI =  
 440 Montreal Neurological Institute

441

442

443

444 **Supplementary Table 17.** Brain activations during trace fear conditioning (CS81+ vs. CS-) for healthy  
 445 controls.

AAL Region	Cluster <i>p</i> value FWER	N voxels	<i>t</i>	MNI (x,y,z)	Peak <i>p</i> value uncorrected
Thalamus	<0.001	439	10.08	6, -21, 0	<0.001
			9.35	-15, -18, 6	<0.001
			8.64	-6, -21, -3	<0.001
Precentral_L	<0.001	197	8.79	-39, -9, 48	<0.001
			5.49	-48, 3, 45	<0.001
SupraMarginal_L	<0.001	276	8.72	-51, -33, 27	<0.001
			6.58	-45, -27, 9	<0.001
			6.34	-54, -18, 24	<0.001
Insula_L	<0.001	147	8.04	-30, 27, 3	<0.001
			7.82	-33, 18, 9	<0.001
			5.45	-51, 6, 3	<0.001
Supp_Motor_Area	<0.001	403	7.99	6, -18, 54	<0.001
			7.57	6, -3, 57	<0.001
			7.06	-3, 3, 54	<0.001
Postcentral_R	<0.001	104	7.75	33, -30, 63	<0.001
			7.56	27, -27, 54	<0.001
Caudate_L	<0.001	28	7.04	-9, 6, 6	<0.001
Insula_R	<0.001	52	6.86	33, 27, 0	<0.001
			6.31	33, 24, 9	<0.001
SupraMarginal_R	<0.001	20	5.83	54, -33, 30	<0.001
Putamen_R	<0.001	20	5.65	30, 0, 0	<0.001

446 *Note:* AAL = Automated Anatomical Labeling, FWER = Family Wise Error Rate, N = Number, MNI =  
 447 Montreal Neurological Institute

448

449

450

451

452

453

454

455 **Supplementary Table 18.** Brain activations during trace fear conditioning (CS81+ vs. CS-) for patients  
 456 with anxiety disorders.

AAL Region	Cluster <i>p</i> value FWER	N voxels	<i>t</i>	MNI (x,y,z)	Peak <i>p</i> value uncorrected
Supp_Motor_Area	<0.001	460	8.94	0, -6, 60	<0.001
			7.49	6, 6, 54	<0.001
			6.67	6, -27, 54	<0.001
Insula_L	<0.001	253	7.61	-36, 24, 3	<0.001
			5.55	-57, 6, 12	<0.001
			4.67	-51, 3, 3	<0.001
Thalamus	<0.001	99	6.76	3, -21, -6	<0.001
			5.38	9, -15, -6	<0.001
			5	-9, -18, 9	<0.001
Precentral_L	<0.001	442	6.71	-36, -6, 51	<0.001
			6.68	-42, -12, 54	<0.001
			5.63	-51, -3, 42	<0.001
Parietal_Inf_L	<0.001	303	6.51	-54, -39, 39	<0.001
			5.39	-60, -33, 27	<0.001
			5.32	-51, -27, 15	<0.001
Cingulum_Mid	<0.01	79	5.88	-12, -24, 45	<0.001
			4	-15, -39, 51	<0.001
Precentral_R	<0.001	205	5.62	33, -27, 63	<0.001
			5.25	42, -12, 57	<0.001
			4.92	33, -36, 63	<0.001
Insula_R	<0.001	183	5.58	39, 21, 6	<0.001
			5.21	48, 6, 3	<0.001
			4.93	54, 12, 9	<0.001
SupraMarginal_R	<0.01	95	5.55	51, -30, 27	<0.001
			5.03	45, -24, 21	<0.001
Calcarine	<0.001	193	5.09	-9, -90, 3	<0.001
			5.04	3, -81, 3	<0.001
			4.82	9, -87, 6	<0.001

457 *Note:* AAL = Automated Anatomical Labeling, FWER = Family Wise Error Rate, N = Number, MNI =  
 458 Montreal Neurological Institute

459

460

461

462 **Supplementary Table 19.** Brain activations during trace fear conditioning (CS81+ vs. CS50+) for  
 463 healthy controls.

AAL Region	Cluster <i>p</i> value FWER	N voxels	<i>t</i>	MNI (x,y,z)	Peak <i>p</i> value uncorrected
Temporal_Mid_R	<0.001	371	4.9	39, -51, 15	<0.001
			4.63	33, -60, 15	<0.001
			4.41	51, -57, 15	<0.001
Putamen_R	<0.01	142	4.89	30, -6, 0	<0.001
			4.74	24, -6, 9	<0.001
Hippocampus_R			4.34	30, -24, -3	<0.001
Occipital_Mid_L	<0.001	716	4.46	-39, -63, 18	<0.001
			4.37	-36, -36, 15	<0.001
Putamen_L			4.36	-21, -9, 15	<0.001
Thalamus_L			4.16	-11, -22, 6	<0.001
Precentral_R	<0.05	79	4.43	36, -18, 48	<0.001
Postcentral_R			4.3	30, -27, 54	<0.001

464 *Note:* AAL = Automated Anatomical Labeling, FWER = Family Wise Error Rate, N = Number, MNI =  
 465 Montreal Neurological Institute

466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477

478 **Additional analysis - Covariating for biological sex and age**

479 **Supplementary Table 20.** ANCOVA results for the effects group and CS type on SCR, arousal, and  
 480 valence, covariating for biological sex and age during delay conditioning

ANCOVA	Effect	<i>F</i>	<i>df</i>	<i>p</i>	$\eta^2$
SCR	G	5.86	1, 124	.017	.045
	S	4.00	1, 124	.048	.031
	A	0.29	1, 124	.594	.002
	G x S	0.45	1, 124	.505	.004
	CS	6.62	1, 124	.011	.051
	CS x G	0.60	1, 124	.439	.005
	CS x S	0.03	1, 124	.866	<.001
	CS x A	0.82	1, 124	.368	.007
	CS x G x S	3.88	1, 124	.051	.030
Arousal ratings	G	1.46	1, 124	.229	.012
	S	1.51	1, 124	.221	.012
	A	0.08	1, 124	.778	<.001
	G x S	2.92	1, 124	.090	.023
	CS	20.53	1, 124	<.001	.142
	CS x G	0.20	1, 124	.659	.002
	CS x S	3.55	1, 124	.062	.028
	CS x A	1.63	1, 124	.205	.013
	CS x G x S	3.30	1, 124	.071	.026
Valence ratings	G	0.05	1, 124	.822	<.001
	S	0.04	1, 124	.851	<.001
	A	1.11	1, 124	.293	.009
	G x S	0.09	1, 124	.767	<.001
	CS	13.68	1, 124	<.001	.099
	CS x G	0.16	1, 124	.693	<.001
	CS x S	7.39	1, 124	.007	.056
	CS x A	0.21	1, 124	.651	<.001
	CS x G x S	2.69	1, 124	.104	.021

481 *Note:* G=Group, S=Sex, A=Age, CS = CS type

482

483 **Supplementary Table 21.** ANCOVA results for the effects of group and CS type on SCR, arousal, and  
 484 valence, covariating for biological sex and age during fear reversal.

	ANCOVA	Effect	<i>F</i>	<i>df</i>	<i>p</i>	$\eta^2$
SCR		G	1.46	1, 124	.228	.012
		S	0.03	1, 124	.867	<.001
		A	0.02	1, 124	.877	<.001
		G x S	1.06	1, 124	.305	.008
		CS	6.41	1, 124	.013	.049
		CS x G	0.64	1, 124	.425	.005
		CS x S	0.31	1, 124	.579	.002
		CS x A	0.54	1, 124	.463	.004
		CS x G x S	0.95	1, 124	.331	.008
Arousal ratings		G	2.65	1, 124	.106	.021
		S	0.00	1, 124	.946	<.001
		A	2.64	1, 124	.107	.021
		G x S	1.12	1, 124	.293	.009
		CS	17.62	1, 124	<.001	.124
		CS x G	1.83	1, 124	.179	.015
		CS x S	0.16	1, 124	.687	.001
		CS x A	1.69	1, 124	.196	.013
		CS x G x S	2.22	1, 124	.139	.018
Valence ratings		G	0.47	1, 124	.492	.004
		S	1.06	1, 124	.306	.008
		A	0.71	1, 124	.401	.006
		G x S	3.13	1, 124	.079	.025
		CS	12.88	1, 124	<.001	.094
		CS x G	1.33	1, 124	.252	.011
		CS x S	0.10	1, 124	.758	<.001
		CS x A	1.19	1, 124	.277	.010
		CS x G x S	0.89	1, 124	.347	.007

485 *Note:* G=Group, S=Sex, A=Age, CS = CS type

486

487

488

489

490

491

492

493

494 **Supplementary Table 22.** ANCOVA results for the effects of group and CS type on SCR, arousal, and  
 495 valence, covariating for biological sex and age during trace conditioning.

496

ANCOVA	Effect	<i>F</i>	<i>df</i>	<i>p</i>	$\eta^2$
SCR	G	0.06	1, 119	.805	.001
	S	0.00	1, 119	.979	.000
	A	2.83	1, 119	.095	.023
	G x S	3.65	1, 119	.058	.030
	CS <sup>a</sup>	6.75	1.47, 175.26	.004	.054
	CS x G <sup>a</sup>	0.01	1.47, 175.26	.975	.000
	CS x S <sup>a</sup>	1.54	1.47, 175.26	.220	.013
	CS x A <sup>a</sup>	1.59	1.47, 175.26	.210	.013
	CS x G x S <sup>a</sup>	2.40	1.47, 175.26	.109	.020
Arousal Ratings	G	3.79	1, 119	.054	.031
	S	5.12	1, 119	.026	.041
	A	0.23	1, 119	.636	.002
	G x S	1.20	1, 119	.275	.010
	CS <sup>b</sup>	12.04	1.90, 225.95	<.001	.092
	CS x G <sup>b</sup>	2.19	1.90, 225.95	.117	.018
	CS x S <sup>b</sup>	4.72	1.90, 225.95	.011	.038
	CS x A <sup>b</sup>	1.55	1.90, 225.95	.215	.013
CS x G x S <sup>b</sup>	2.43	1.90, 225.95	.093	.020	
Valence Ratings	G	0.18	1, 119	.671	.002
	S	1.29	1, 119	.258	.011
	A	0.42	1, 119	.519	.004
	G x S	0.08	1, 119	.775	.001
	CS <sup>c</sup>	18.36	1.72, 204.34	<.001	.134
	CS x G <sup>c</sup>	1.92	1.72, 204.34	.156	.016
	CS x S <sup>c</sup>	1.13	1.72, 204.34	.320	.009
	CS x A <sup>c</sup>	4.81	1.72, 204.34	.013	.039
CS x G x S <sup>c</sup>	0.12	1.72, 204.34	.857	.001	

497 *Note:* G=Group, S=Sex, A=Age, CS = CS type. Greenhouse-Geisser corrected values identified with  
 498 lowercase letters.

499 <sup>a</sup>: Mauchly's *W* = .642, *p* < .001, Greenhouse-Geisser  $\epsilon$  = .736

500 <sup>b</sup>: Mauchly's *W* = .947, *p* = .039, Greenhouse-Geisser  $\epsilon$  = .949

501 <sup>c</sup>: Mauchly's *W* = .835, *p* < .001, Greenhouse-Geisser  $\epsilon$  = .859

502

503

504 **Additional analyses. Adding task order as factor**

505 **Supplementary Table 23.** Significant differences in brain activation during early delay fear conditioning  
 506 (CS+>CS-) between patients with anxiety disorders and healthy controls when task order was included  
 507 as a factor.

AAL Region	Cluster <i>p</i> value FWER	N voxels	<i>t</i>	MNI (x,y,z)	Peak <i>p</i> value uncorrected
Frontal_Mid_L	<0.05	70	3.99	-27, 33, 21	<0.001
			3.69	-30, 45, 12	<0.001

508 *Note:* AAL = Automated Anatomical Labeling, FWER = Family Wise Error Rate, N = Number, MNI =  
 509 Montreal Neurological Institute

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526 **Supplementary Table 24:** ANOVA results for the effects of group, CS type, and task order (delayed-  
 527 reversal first versus trace first) on SCR during delay fear conditioning.

ANOVA	Effect	F	DF	p	Eta2p
SCR	G	6.07	1, 125	.015	.046
	TO	.52	1, 125	.472	.004
	G x TO	.09	1, 125	.771	.001
	CS	71.78	1, 125	<.001	.365
	CS x G	.33	1, 125	.568	.003
	CS x TO	.17	1, 125	.685	.001
	CS x G x TO	.01	1, 125	.928	<.001
Arousal ratings	G	2.16	1, 125	.145	.017
	TO	3.12	1, 125	.080	.024
	G x TO	2.79	1, 125	.100	.022
	CS	276.83	1, 125	<.001	.689
	CS x G	.34	1, 125	.563	.003
	CS x TO	1.25	1, 125	.265	.010
	CS x G x TO	.01	1, 125	.942	<.001
Valence ratings	G	.04	1, 125	.849	<.001
	TO	3.17	1, 125	.077	.025
	G x TO	1.29	1, 125	.258	.010
	CS	274.85	1, 125	<.001	.687
	CS x G	.24	1, 125	.622	.002
	CS x TO	3.26	1, 125	.074	.025
	CS x G x TO	.25	1, 125	.619	.002

Note: G = Group; TO = Task Order; CS = CS type.

528  
 529  
 530

531 **Supplementary Table 25:** ANOVA results for the effects of group, CS type, and task order (delayed-  
 532 reversal first versus trace first) on SCR during reversal conditioning.

533

ANOVA	Effect	F	DF	p	Eta2p
SCR	G	1.71	1, 125	.193	.014
	TO	1.44	1, 125	.233	.011
	G x TO	.56	1, 125	.455	.004
	CS	96.20	1, 125	<.001	.408
	CS x G	.776	1, 125	.380	.006
	CS x TO	1.41	1, 125	.237	.011
	CS x G x TO	.09	1, 125	.763	.001
Arousal ratings	G	3.20	1, 125	.076	.025
	TO	4.92	1, 125	.028	.038
	G x TO	.03	1, 125	.860	<.001
	CS	218.95	1, 125	<.001	.637
	CS x G	2.23	1, 125	.138	.017
	CS x TO	.23	1, 125	.636	.002
	CS x G x TO	.17	1, 125	.685	.001
Valence ratings	G	.69	1, 125	.408	.005
	TO	2.98	1, 125	.087	.023
	G x TO	.44	1, 125	.509	.003
	CS	164.53	1, 125	<.001	.568
	CS x G	1.02	1, 125	.314	.008
	CS x TO	1.74	1, 125	.189	.014
	CS x G x TO	.374	1, 125	.542	.003

534 Note: G = Group; TO = Task Order; CS = CS type.

535

536

537 **Supplementary Table 26.** ANOVA results for the effects of group, CS type, and task order (delayed-  
 538 reversal first versus trace first) on SCR during trace fear conditioning.

ANOVA	Effect	F	DF	p	Eta2p
SCR	G	<.001	1, 120	.980	<.001
	TO	.14	1, 120	.710	.001
	G x TO	.004	1, 120	.953	<.001
	CS <sup>a</sup>	43.65	1.46, 175.15	<.001	.266
	CS x G <sup>a</sup>	.002	1.46, 175.15	.990	<.001
	CS x TO <sup>a</sup>	.03	1.46, 175.15	.933	<.001
	CS x G x TO <sup>a</sup>	.15	1.46, 175.15	.795	.001
Arousal ratings	G	3.57	1, 120	.061	.029
	TO	.11	1, 120	.740	<.001
	G x TO	.89	1, 120	.346	.007
	CS <sup>b</sup>	127.85	1.86, 223.08	<.001	.516
	CS x G <sup>b</sup>	2.56	1.86, 223.08	.084	.021
	CS x TO <sup>b</sup>	2.49	1.86, 223.08	.090	.020
	CS x G x TO <sup>b</sup>	2.08	1.86, 223.08	.131	.017
Valence ratings	G	.06	1, 120	.801	<.001
	TO	4.92	1, 120	.028	.039
	G x TO	.01	1, 120	.920	<.001
	CS <sup>c</sup>	108.14	1.70, 203.96	<.001	.474
	CS x G <sup>c</sup>	2.44	1.70, 203.96	.098	.020
	CS x TO <sup>c</sup>	4.71	1.70, 203.96	.014	.038
	CS x G x TO <sup>c</sup>	1.66	1.70, 203.96	.196	.014

539 Note: G = Group; TO = Task Order; CS = CS type. Greenhouse-Geisser corrected values identified  
 540 with lowercase letters.

541 a: Mauchly's  $W = .630$ ,  $p < .001$ , Greenhouse-Geisser  $\epsilon = .730$

542 b: Mauchly's  $W = .924$ ,  $p = .009$ , Greenhouse-Geisser  $\epsilon = .930$

543 c: Mauchly's  $W = .823$ ,  $p < .001$ , Greenhouse-Geisser  $\epsilon = .850$

544

545

546


547

548

549 **SUPPLEMENTARY FIGURES**

550 **Delay Fear Conditioning**

551 **Preconditioning**



552

553 **Supplementary Figure 1:** Responses during preconditioning in the delay conditioning/reversal task in  
554 healthy controls (n=98) and patients with anxiety disorders (n=33). LEFT: SCR (last trial) (A), subjective  
555 ratings of arousal (B) and valence (C) RIGHT: SCR (last trial) (D) subjective ratings of arousal (E) and  
556 valence (F). SCR = skin conductance response. CS = conditioned stimuli. Error bars indicate standard  
557 error of the mean (SEM).

558

559

560

561

562

563

564

565

566


567

568

569

570 **Trace Fear Conditioning**

571 **Preconditioning**



572 **Supplementary Figure 2:** Responses during preconditioning in the trace conditioning task in healthy  
573 controls (n=93) and patients with anxiety disorders (n=31). LEFT: SCR (last trial) (A), subjective ratings  
574 of arousal (B) and valence (C) RIGHT: SCR (last trial) (D) subjective ratings of arousal (E) and valence  
575 (F). SCR = skin conductance response. CS = conditioned stimuli. Error bars indicate standard error of  
576 the mean (SEM). \* $p < 0.01$ .

577

578

579

580

581

582

583

584

585

586


587

588

589

590

591 Conditioning – contrast CS81+ > CS50+



592

593 **Supplementary Figure 3.** Clusters of fMRI activations (CS81+ > CS50+) for trace conditioning in  
594 healthy controls

595

596

597 **SUPPLEMENTARY REFERENCES**

598

- 599 1 Buela-Casal G, Guillén-Riquelme A, Seisdedos Cubero N. *Cuestionario de Ansiedad*  
600 *Estado-Rasgo*. 9th ed. TEA Ediciones: Madrid, 2016.
- 601 2 Spielberg CD, Gorsuch RL, Lushene RE. *Manual for the State-Trait Inventory*.  
602 Consulting Psychological Press: Palo Alto: CA, 1970.
- 603 3 Ferrando L, Franco A, Soto M, Bobes J, Soto O, Franco L *et al*. *MINI Entrevista*  
604 *Neuropsiquiátrica Internacional*. Instituto IAP: Madrid, 1998.
- 605 4 Sheehan D V, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E *et al*. The  
606 Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and  
607 validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J*  
608 *Clin Psychiatry* 1998; 59 Suppl 20: 22–33.
- 609 5 Freeston MH, Rheaume J, Letarte H, Dugas MJ, Ladouceur R. Intolerance of  
610 Uncertainty Scale. *PsycTESTS Dataset* 2012. doi:10.1037/T01110-000.
- 611 6 González Rodríguez M, Cubas León R, Rovella AT, Darías Herrera M. Adaptación  
612 española de la escala de intolerancia hacia la incertidumbre: procesos cognitivos,  
613 ansiedad y depresión. *Psicología y Salud* 2006; 16: 219–233.
- 614 7 Bobes J, Badía X, Luque A, García M, González MP, Dal-Ré R. Validation of the  
615 Spanish version of the Liebowitz social anxiety scale, social anxiety and distress scale  
616 and Sheehan disability inventory for the evaluation of social phobia. *Medicina Clínica*  
617 *(Barcelona)* 1999; 112: 130–138.
- 618 8 Liebowitz MR. Social Phobia. *Mod Probl Pharmacopsychiatry* 1987; : 141–173.
- 619 9 Bobes J, García-Calvo C, Prieto R, García-García M, Rico-Villademoros F, Grupo  
620 Español de Trabajo para la validación de la versión española de la Escala de  
621 Detección del Trastorno de Ansiedad Generalizada según DSM-IV (Escala de TAG  
622 de Carrol y Davidson)). Psychometric properties of the Spanish version of the  
623 screening scale for DSM-IV Generalized Anxiety Disorder of Carroll and Davidson.  
624 *Actas Esp Psiquiatr* 2006; 34: 83–93.
- 625 10 Carroll BJ, Davidson JRT. Screening scale for DSM-IV GAD. *Copyright* 2000.
- 626 11 Meyer TJ, Miller ML, Metzger RL, Borkovec T. Development and validation of the  
627 Penn State Worry Questionnaire. *Behaviour research and therapy* 1990; 28: 487–495.
- 628 12 Sandín B, Chorot P, Valiente RM, Lostao L. Validación española del cuestionario de  
629 preocupación PSWQ : estructura factorial y propiedades psicométricas. *Revista de*  
630 *Psicopatología y Psicología Clínica* 2009; 14: 107–122.
- 631 13 Bados A, Solanas A, Andrés R. Psychometric properties of the Spanish version of  
632 Depression, Anxiety and Stress Scales (DASS). *Psicothema* 2005; 17: 679–683.
- 633 14 Lovibond SH, Lovibond PF. Depression Anxiety Stress Scales. *PsycTESTS Dataset*  
634 1995. doi:10.1037/T01004-000.
- 635 15 Tustison NJ, Avants BB, Cook PA, Yuanjie Zheng, Egan A, Yushkevich PA *et al*.  
636 N4ITK: Improved N3 Bias Correction. *IEEE Trans Med Imaging* 2010; 29: 1310–1320.
- 637 16 Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL.  
638 *Neuroimage* 2012; 62: 782–790.
- 639 17 Dale AM, Fischl B, Sereno MI. Cortical Surface-Based Analysis: I. Segmentation and  
640 Surface Reconstruction. *NeuroImage (Orlando, Fla)* 1999; 9: 179–194.
- 641 18 Klein A, Ghosh SS, Bao FS, Giard J, Häme Y, Stavsky E *et al*. Mindboggling  
642 morphometry of human brains. *PLoS Comput Biol* 2017; 13: e1005350–e1005350.

- 643 19 Fonov V, Evans A, McKinstry R, Almli C, Collins D. Unbiased nonlinear average age-  
644 appropriate brain templates from birth to adulthood. *NeuroImage (Orlando, Fla)* 2009;  
645 47: S102–S102.
- 646 20 Esteban O, Ciric R, Finc K, Blair RW, Markiewicz CJ, Moodie CA *et al.* Analysis of  
647 task-based functional MRI data preprocessed with fMRIPrep. *Nat Protoc* 2020; 15:  
648 2186–2202.
- 649 21 Gorgolewski K, Burns CD, Madison C, Clark D, Halchenko YO, Waskom ML *et al.*  
650 Nipype: a flexible, lightweight and extensible neuroimaging data processing  
651 framework in python. *Front Neuroinform* 2011; 5: 13–13.
- 652 22 Greve DN, Fischl B. Accurate and robust brain image alignment using boundary-  
653 based registration. *NeuroImage (Orlando, Fla)* 2009; 48: 63–72.
- 654 23 Cox RW, Hyde JS. Software tools for analysis and visualization of fMRI data. *NMR*  
655 *Biomed* 1997; 10: 171–178.
- 656 24 Jenkinson M, Bannister P, Brady M, Smith S. Improved Optimization for the Robust  
657 and Accurate Linear Registration and Motion Correction of Brain Images. *NeuroImage*  
658 *(Orlando, Fla)* 2002; 17: 825–841.
- 659 25 Lanczos C. Evaluation of Noisy Data. *Journal of the Society for Industrial and Applied*  
660 *Mathematics Series B, Numerical analysis* 1964; 1: 76–85.
- 661 26 Pruim RHR, Mennes MJJ, Rooij D van, Llera A, Buitelaar JK, Beckmann CF. ICA-  
662 AROMA: A robust ICA-based strategy for removing motion artifacts from fMRI data.  
663 *NeuroImage (Orlando, Fla)* 2015; 112: 267–277.
- 664 27 Behzadi Y, Restom K, Liau J, Liu TT. A component based noise correction method  
665 (CompCor) for BOLD and perfusion based fMRI. *NeuroImage (Orlando, Fla)* 2007; 37:  
666 90–101.
- 667 28 Power JD, Mitra A, Laumann TO, Snyder AZ, Schlaggar BL, Petersen SE. Methods to  
668 detect, characterize, and remove motion artifact in resting state fMRI. *NeuroImage*  
669 *(Orlando, Fla)* 2014; 84: 320–341.

670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691